introduct
salbutamol
short
act
agonist
commonli
use
treat
airway
diseas
aim
aim
studi
investig
transport
salbutamol
sulfat
differenti
primari
human
bronchial
epitheli
cell
cell
line
method
human
primari
bronchial
epitheli
cell
cultur
airliquid
interfac
least
day
day
respect
salbutamol
sulfat
ss
dri
powder
form
deposit
cell
layer
use
twin
stage
imping
tsi
flow
rate
lmin
second
transport
ss
studi
hour
drug
penetr
across
cell
layer
assess
high
perform
liquid
chromatographi
hplc
result
percentag
transport
ss
differenti
primari
human
bronchial
epitheli
cell
n
min
posit
relationship
amount
ss
dri
powder
deposit
cell
layer
p
howev
relationship
appar
cell
p
n
conclus
studi
transport
salbutamol
sulfat
dri
powder
deposit
epitheli
cell
differenti
primari
human
bronchial
epitheli
cell
would
repres
vivo
physiolog
transport
rate
ss
furthermor
data
could
suggest
dose
ss
taken
patient
deposit
airway
correl
transport
ss
airway
epithelium
turn
would
affect
concentr
drug
airway
smooth
muscl
level
vaughan
stevanov
miljev
b
ristovski
z
relan
v
goh
f
bowman
r
fong
k
yang
uq
thorac
research
centr
intern
laboratori
air
qualiti
health
qut
introduct
vitro
studi
use
primari
cell
line
physiolog
condit
may
improv
current
understand
advers
health
effect
associ
air
pollut
aim
aim
studi
investig
cellular
respons
primari
human
bronchial
epitheli
cell
hbec
neat
modifi
diesel
emiss
airliquid
interfac
ali
method
primari
hbec
establish
uq
thorac
research
centr
cultur
differenti
ali
day
function
characterist
cell
layer
determin
seri
stain
assess
cilia
growth
mucu
product
primari
hbec
expos
diesel
emiss
gener
intern
laboratori
air
qualiti
health
hbec
respons
diesel
emiss
measur
cell
viabil
cytokin
secret
result
hbec
demonstr
mucociliari
phenotyp
day
differenti
ali
neat
diesel
emiss
caus
reduct
cell
viabil
increas
cytokin
secret
attenu
remov
organ
content
particl
result
summar
tabl
n
indic
signific
differ
p
conclus
primari
hbec
respons
diesel
emiss
sensit
composit
organ
content
may
strong
mediat
advers
health
effect
associ
diesel
emiss
exposur
aim
suggest
talc
pleurodesi
suboptim
outcom
treatment
pleural
effus
associ
mesothelioma
aim
studi
assess
success
talc
pleurodesi
medic
thoracoscopi
mesothelioma
malign
effus
singl
centr
studi
retrospect
case
seri
sequenti
medic
thoracoscopi
perform
malign
effus
cairn
success
pleurodesi
defin
one
pleural
intervent
requir
result
case
malign
pleural
effus
confirm
medic
thoracoscopi
talc
pleurodes
perform
overal
success
rate
per
cent
mesothelioma
subgroup
consist
patient
overal
success
rate
per
cent
conclus
talc
pleurodesi
medic
thoracoscopi
highli
success
intervent
palli
treatment
mesothelioma
relat
malign
effus
gener
background
st
vincent
hospit
melbourn
offer
specialist
referr
clinic
patient
suspect
proven
thorac
malign
provid
multidisciplinari
diagnost
manag
approach
servic
major
tertiari
referr
centr
region
metropolitan
patient
victoria
number
patient
refer
servic
found
malign
diseas
spectrum
benign
diagnos
tumour
characterist
patient
malign
diagnos
examin
previous
aim
evalu
demograph
final
diagnos
benign
malign
tumour
characterist
investig
perform
patient
refer
specialist
servic
suspect
proven
thorac
malign
method
retrospect
audit
st
vincent
hospit
combin
lung
clinic
databas
conduct
januari
januari
inclus
referr
obtain
review
initi
workup
diagnosi
result
referr
combin
lung
clinic
primari
lung
cancer
mesothelioma
metastat
thorac
lesion
malign
lesion
unidentifi
primari
site
benign
lesion
benign
lesion
includ
wide
spectrum
patholog
diagnos
use
combin
modal
includ
surgic
intervent
intervent
radiolog
bronchial
endoscopi
surveil
imag
conclus
multidisciplinari
clinic
investig
manag
known
suspect
thorac
malign
requir
access
wide
rang
diagnost
tool
specialti
servic
well
knowledg
manag
wide
rang
benign
condit
malign
diseas
primari
lung
cancer
diagnost
manag
decis
complex
requir
involv
multipl
specialti
thorac
surgic
servic
import
compon
clinic
mani
patient
advanc
primari
lung
cancer
benign
diseas
secondari
malign
benefit
involv
specialist
servic
introduct
time
diagnosi
lung
cancer
traumat
period
patient
scant
literatur
regard
need
lung
cancer
patient
time
diagnosi
import
ensur
target
resourc
need
patient
period
southern
rapid
access
lung
cancer
clinic
joint
clinic
run
specialist
physician
specialist
lung
cancer
nurs
cohort
patient
jointli
evalu
care
coordin
time
diagnosi
aim
accur
determin
need
lung
cancer
patient
time
diagnosi
method
identifi
cohort
patient
southern
rapid
access
lung
cancer
clinic
perform
need
analysi
time
diagnosi
result
follow
domain
assess
medic
commun
psycholog
emot
daili
live
financi
respiratori
symptom
spiritu
existenti
social
amidst
domain
highest
need
indic
respond
domain
medic
commun
interestingli
respiratori
symptom
financi
issu
domain
major
respond
score
signific
need
conclus
pilot
survey
suggest
major
need
felt
patient
lung
cancer
time
diagnosi
domain
medic
commun
resourc
need
target
support
patient
provid
prompt
accur
inform
includ
result
investig
stage
process
treatment
option
prognosi
respiratori
symptom
financ
minor
issu
respond
newli
diagnos
lung
cancer
limit
publish
data
look
surviv
primari
nonsmal
cell
lung
cancer
nsclc
particularli
australian
cohort
method
local
clinic
practic
inform
collect
prospect
databas
case
present
multidisciplinari
lung
cancer
meet
period
april
march
analys
patient
nsclc
identifi
n
surviv
data
obtain
nsclc
case
n
via
hospit
gener
practition
record
well
registri
birth
death
marriag
lung
cancer
stage
base
edit
iaslc
tnm
classif
mortal
data
surviv
time
calcul
accord
clinic
stage
result
five
year
surviv
stage
nsclc
stratifi
stage
surviv
stage
stage
ii
stage
iii
stage
iv
overal
median
surviv
month
stratifi
stage
month
stage
month
stage
ii
month
stage
iii
month
stage
iv
diseas
patient
underw
surgic
resect
cur
intent
surviv
keep
publish
australian
data
conclus
surviv
rate
stage
ii
iii
iv
nsclc
compar
intern
publish
cohort
contrast
allcaus
mortal
rate
stage
nsclc
appear
higher
expect
howev
rate
surgic
cure
keep
publish
data
introduct
mdsc
heterogen
popul
myeloid
progenitor
precursor
macrophag
granulocyt
dendrit
cell
tcell
immunosuppress
activ
suggest
character
express
mdsc
number
increas
nsclc
implic
respons
therapi
potenti
reduc
immun
product
increas
larginin
convers
nitric
oxid
nitritenitr
nox
aim
studi
aim
assess
nox
gener
level
serum
ebc
patient
nsclc
control
includ
smoker
chronic
obstruct
pulmonari
diseas
copd
smoke
known
caus
nsclc
mani
individu
nsclc
also
copd
asthma
act
benign
control
inflammatori
disord
method
sampl
subject
nsclc
compar
copd
asthma
healthi
smoker
exsmok
neversmok
level
serum
ebc
assess
use
enzymelink
immunosorb
assay
elisa
nox
use
modifi
fluorometr
adapt
griess
method
nonsmok
exsmok
smoker
asthmat
copd
nsclc
result
nox
product
increas
serum
subject
nsclc
nsclc
vs
nonsmok
p
ebc
also
tend
elev
serum
smoker
subject
nsclc
reach
signific
serum
hand
detect
one
subject
asthma
anoth
nsclc
ebc
level
mostli
level
detect
conclus
nox
product
increas
nsclc
larger
studi
need
confirm
observ
thoma
r
aim
human
breath
contain
volatil
biomark
could
use
diagnos
lung
diseas
may
achiev
faim
technolog
method
separ
gasphas
ion
atmospher
pressur
ambient
temperatur
compound
ioniz
pass
asymmetr
charg
field
ion
separ
mobil
vari
electr
field
compens
voltag
cv
use
filter
ion
electrod
channel
detector
use
rang
dispers
field
df
differ
ioniz
entiti
breath
detect
aim
adapt
faim
first
analys
breath
normal
subject
intend
later
map
diagnost
ion
pattern
lung
diseas
method
breath
normal
healthi
subject
cool
ice
exhal
breath
condens
ebc
retain
gaseou
phase
mix
dri
clean
air
drawn
faim
analys
neg
pressur
separ
experi
ebc
collect
previous
vapour
neg
pressur
analys
similar
manner
result
breath
water
vapour
gener
domin
overwhelm
signal
humid
sampl
higher
humid
accomplish
condens
breath
water
mix
dri
air
faim
show
similar
spectra
healthi
subject
food
beverag
consum
subject
prior
breath
analysi
ad
addit
peak
spectra
indic
need
assess
breathprint
analysi
water
vapour
breath
lower
separ
effici
faim
significantli
consist
peak
within
healthi
subject
observ
recent
consumpt
food
substanc
like
alter
analysi
hank
shield
p
tointon
j
page
b
kenni
l
yang
bowman
r
marshal
h
fong
k
school
medicin
univers
queensland
qld
depart
thorac
medicin
princ
charl
hospit
qld
central
integr
region
cancer
servic
bowen
hill
qld
cancer
care
servic
royal
brisban
women
hospit
qld
aim
nonurban
cancer
popul
australia
poorer
health
outcom
reduc
access
specialist
servic
compar
urban
counterpart
studi
aim
determin
differ
journey
nonurban
urban
patient
suspect
lung
cancer
refer
tertiari
hospit
queensland
method
prospect
cohort
studi
consecut
patient
refer
tertiari
hospit
queensland
suspect
lung
cancer
februari
august
main
outcom
patient
journey
symptom
onset
diagnosi
type
referr
journey
time
diagnosi
extract
hospit
electron
record
patient
refer
investig
pattern
outofpocket
expens
patientpercept
care
travel
accommod
need
obtain
selfreport
questionnair
mail
consent
patient
time
referr
onemonth
follow
result
elig
patient
identifi
return
questionnair
time
referr
first
specialist
appoint
pattern
referr
investig
diagnosi
patient
percept
care
similar
nonurban
urban
patient
total
outofpocket
expens
significantli
greater
nonurban
patient
median
nonurban
urban
p
distanc
residenti
address
hospit
correl
strongli
day
paid
work
r
p
conclus
nonurban
patient
suspect
lung
cancer
incur
higher
outofpocket
expens
day
paid
work
otherwis
significantli
disadvantag
journey
diagnosi
compar
urban
patient
acknowledg
nhmrc
practition
fellowship
kf
introduct
increas
trend
literatur
suggest
multidisciplinari
tracheostomi
team
may
improv
safeti
enhanc
outcom
promot
excel
aim
evalu
effect
introduct
tr
patient
outcom
staff
attitud
conclus
although
contribut
improv
aspect
staff
knowledg
confid
result
suggest
multidisciplinari
tr
limit
effect
patient
outcom
centr
limit
studi
includ
small
sampl
size
extrem
heterogen
patient
characterist
better
understand
patient
group
may
help
identifi
patient
may
benefit
multidisciplinari
team
manag
formul
referr
guid
introduct
malign
pleural
effus
mpe
common
ipc
talc
pleurodesi
approv
treatment
mpe
equal
efficaci
provid
symptom
relief
shown
recent
random
studi
recent
patientchoic
studi
show
mpe
patient
chose
ipc
treatment
spent
significantli
fewer
day
hospit
requir
fewer
addit
pleural
procedur
compar
chose
talc
pleurodesi
aim
ampl
design
verifi
benefit
ipc
pleurodesi
reduc
inpati
care
day
primari
endpoint
total
number
day
hospit
caus
admiss
trial
intervent
death
end
studi
period
design
patient
n
symptomat
mpe
random
ipc
talc
slurri
pleurodesi
random
stratifi
mesothelioma
vs
cancer
presenc
vs
absenc
trap
lung
selfreport
qualityoflif
breathless
score
advers
event
healthcar
cost
record
particip
follow
minimum
month
recruit
death
progress
date
commenc
recruit
juli
particip
enrol
five
centr
feed
hospit
western
australia
nsw
queensland
auckland
wellington
sever
addit
centr
join
studi
upon
local
ethic
approv
conclus
studi
help
determin
ipc
treatment
reduc
inpati
care
day
data
direct
impact
patient
care
inform
health
polici
decis
given
larg
number
patient
develop
mpe
everi
year
implic
healthcar
cost
also
substanti
aim
endobronchi
ultrasoundguid
transbronchi
needl
aspir
ebustbna
becom
wide
adopt
major
tertiari
centr
effect
minim
invas
diagnost
tool
evalu
lesion
adjac
respiratori
tract
howev
perform
ebustbnaha
well
studi
region
centr
ebu
first
introduc
centr
servic
northern
tasmania
novemb
report
singleoper
experi
ebustbna
compar
exist
practic
convent
tbna
regard
clinic
util
diagnost
accuraci
safeti
ebustbnawa
superior
convent
tbnain
evalu
malign
higher
sensit
vs
higher
neg
predict
valu
vs
diagnost
yield
ebustbna
sarcoidosi
conclus
experi
suggest
ebustbna
perform
safe
effect
region
centr
maintain
high
diagnost
accuraci
compar
major
tertiari
centr
therefor
conclud
feasibl
perform
ebustbna
region
centr
major
complic
observ
studi
period
hnin
k
bowden
jj
respiratori
sleep
servic
southern
adelaid
local
health
network
flinder
medic
centr
adelaid
sa
aim
pulmonari
caviti
thickwal
greater
mm
cystic
parenchym
mass
may
fill
air
fluid
underli
aetiolog
may
due
varieti
process
includ
infect
neoplasm
vasculitid
moreov
diagnosi
infect
abscess
often
requir
exclus
process
number
investig
use
identifi
caus
includ
bronchoscopi
biopsi
therefor
process
achiev
final
diagnosi
aetiolog
caviti
prolong
challeng
sought
determin
aetiolog
lesion
diagnos
region
last
three
year
clinic
util
diagnost
procedur
method
patient
n
underw
bronchoscopi
flinder
medic
centr
assess
radiolog
evid
pulmonari
cavitari
lesion
patient
identifi
case
note
review
result
twenti
four
case
n
identifi
infecti
aetiolog
total
durat
achiev
final
diagnosi
vari
day
howev
diagnos
less
day
case
bronchoscopi
enabl
diagnosi
crp
wall
thick
predict
associ
final
diagnosi
tuberculosi
identifi
cohort
conclus
bronchoscopi
remain
use
tool
diagnosi
consider
delay
achiev
final
diagnosi
observ
minor
case
diagnost
algorithm
may
reduc
delay
diagnosi
introduct
flexiblerigid
pleuroscopi
use
tool
workup
pleural
effus
small
biopsi
channel
often
limit
size
tissu
obtain
especi
patient
thicken
pleura
pilot
studi
evalu
use
safeti
use
cryoprob
obtain
pariet
pleural
biopsi
flexirigid
pleuroscopi
method
singl
centr
prospect
pilot
studi
diagnost
pleuroscopi
perform
patient
suspect
pleural
malign
use
flexirigid
pleuroscop
one
two
experienc
oper
addit
cryoprob
biopsi
obtain
oper
complet
standard
pleuroscop
examin
biopsi
use
flexibl
forcep
ffb
rigid
forcep
rfb
via
second
entri
port
flexibl
autoclav
cryoprob
mm
diamet
activ
second
obtain
cryobiopsi
biopsi
site
assess
bleed
histolog
sampl
review
random
order
specialist
respiratori
pathologist
blind
patient
ident
biopsi
techniqu
introduct
adequ
analgesia
pleural
procedur
remain
challeng
intervent
pulmonolog
methoxyfluran
establish
profil
manag
sever
pain
trauma
medicin
advantag
patientcontrol
analgesia
minim
risk
respiratori
depress
aim
assess
efficaci
toler
methoxyfluran
pleural
procedur
method
prospect
studi
consecut
consent
patient
undergo
invas
pleural
procedur
concord
hospit
februari
august
patient
inhal
methoxyfluran
prior
standard
local
anaesthet
infiltr
procedur
site
iv
access
avail
supplementari
opiat
analgesia
need
patient
oper
questionnair
regard
efficaci
toler
methoxyfluran
conduct
pleural
procedur
dose
opiat
requir
record
result
eighteen
invas
pleural
procedur
perform
time
period
mean
age
year
rang
pleural
procedur
includ
intercost
cathet
insert
fr
selding
techniqu
one
pleural
aspir
two
tunnel
intercost
cathet
two
medic
pleuroscopi
one
tunnel
intercost
cathet
remov
underli
patholog
malign
seven
case
averag
pain
score
postprocedur
correl
well
oper
report
pain
score
averag
anxieti
level
cough
commonli
report
side
effect
occur
patient
requir
addit
opiat
analgesia
procedur
methoxyfluran
well
toler
patient
would
happi
use
futur
procedur
conclus
methoxyfluran
provid
effect
analgesia
well
toler
minim
side
effect
futur
random
control
studi
elucid
use
methoxyfluran
set
compar
current
standard
practic
introduct
sever
wellrecogn
advers
complic
associ
blind
procedur
ie
base
clinic
examin
cxr
includ
mortal
relat
drain
misplac
aim
determin
accuraci
clinic
examin
select
safe
site
thoracentesi
busi
thorac
ward
studi
perform
prospect
inpati
admit
tertiari
teach
hospit
pleural
effus
patient
five
clinician
vari
level
experi
ask
determin
safe
site
thoracentesi
clinician
experi
defin
base
number
procedur
perform
within
last
month
level
least
experienc
level
experienc
view
radiolog
clinician
examin
patient
blind
previou
examin
identifi
safe
site
pleural
drainag
small
group
train
physician
success
complet
accredit
thorac
ultrasound
cours
immedi
examin
select
site
ultrasound
determin
safeti
base
predefin
criterion
presenc
fluid
cm
perpendicular
chosen
site
result
total
examin
perform
patient
site
select
base
clinic
examin
safe
thoracentesi
examin
site
identifi
safe
among
select
site
error
note
identifi
ultrasound
reflect
underli
spleen
n
fluid
cm
n
liver
n
diaphragm
n
introduct
fraction
exhal
nitric
oxid
feno
noninvas
tool
commonli
use
surrog
marker
eosinophil
airway
inflamm
independ
associ
increas
food
specif
ige
individu
peanut
allergi
asthma
risk
factor
anaphalaxi
risk
increas
proport
asthma
sever
retrospect
studi
childhood
peanut
allergi
demonstr
serum
ige
level
peanut
allergen
ara
skin
prick
test
spt
may
help
predict
clinic
reaction
food
challeng
unclear
whether
use
feno
conjunct
spt
andor
specif
ige
ara
diagnost
valu
predict
peanut
allergi
aim
explor
util
feno
noninvas
screen
tool
children
suspect
peanut
allergi
oral
food
challeng
ofc
method
recruit
particip
cohort
consecut
children
schedul
openlabel
peanut
ofc
paediatr
allergist
particip
underw
spt
sensit
whole
peanut
extract
serum
collect
ara
specif
ige
feno
also
measur
cooper
children
challeng
ofc
assess
reaction
undertaken
clinician
blind
test
result
introduct
heat
humidifi
highflow
air
via
nasal
prong
hfnp
ad
oxygen
use
provid
continu
posit
pressur
cpap
infant
need
inpati
respiratori
support
hfnp
therapi
may
use
indic
tradit
cpap
deliv
via
nasopharyng
tube
facemask
technolog
deliv
hfnp
outpati
set
recent
becom
commerci
avail
outpati
hfnp
therapi
may
better
toler
standard
mask
cpap
hfnp
also
offer
conveni
deliveri
interfac
nasal
cannula
may
avoid
side
effect
associ
long
term
facemask
use
aim
describ
experi
use
hfnp
therapi
infant
outpati
set
method
retrospect
chart
review
infant
month
age
discharg
home
hfnp
therapi
tertiari
paediatr
hospit
result
infant
f
week
gestat
identifi
requir
prolong
ventil
develop
chronic
lung
diseas
comorbid
includ
pulmonari
interstiti
glycogenosi
pulmonari
hypertens
craniofaci
airway
abnorm
laryngomalacia
tracheobronchomalacia
genet
condit
noonan
chromosom
delet
commenc
hfnp
therapi
inpati
age
month
follow
unsuccess
wean
cpap
low
flow
oxygen
prior
discharg
indic
outpati
hfnp
therapi
includ
inabl
toler
facemask
cpap
cpap
unsuccess
due
inappropri
mask
fit
parent
refus
tracheostomi
cpap
depend
caregiv
assess
unabl
manag
cpap
tracheostomi
durat
outpati
hfnp
therapi
day
discharg
year
complic
secondari
hfnp
therapi
record
conclus
hfnp
therapi
use
success
support
discharg
patient
unabl
wean
standard
cpap
low
flow
oxygen
background
acut
asthma
one
common
caus
childhood
emerg
associ
viral
infect
although
eczema
atopi
recogn
risk
factor
sever
asthma
factor
associ
recoveri
follow
exacerb
well
understood
aim
children
hospit
nonhospit
asthma
exacerb
describ
point
preval
respiratori
virusesatyp
bacteria
use
polymeras
chain
reaction
pcr
b
evalu
impact
respiratori
virusesatyp
bacteria
eczema
atopi
acut
sever
clinic
recoveri
method
children
age
year
present
acut
asthma
emerg
depart
hospit
recruit
nasopharyng
aspir
allergen
skin
prick
test
perform
asthma
qualiti
life
questionnair
parent
pacqlq
valid
daili
diari
score
asthma
record
day
respect
result
pcr
virusesatyp
bacteria
posit
children
human
rhinoviru
codetect
pneumonia
c
pneumonia
rare
detect
presenc
microorgan
littl
impact
acut
asthma
recoveri
outcom
children
eczema
significantli
slower
asthma
recoveri
ie
higher
asthma
diari
score
day
ci
p
ci
p
ci
p
respect
wherea
children
atopi
significantli
like
relaps
repres
medic
care
day
ci
p
conclus
virus
associ
asthma
exacerb
appear
influenc
asthma
recoveri
contrast
eczema
associ
delay
recoveri
acut
asthma
atopi
associ
asthma
relaps
introduct
protract
bacteri
bronchiti
pbb
common
treatabl
caus
chronic
wet
cough
children
mechan
understood
aim
investig
interleukin
il
pathway
neutrophil
gene
express
signatur
pbb
method
bronchoalveolar
lavag
bal
collect
children
experiment
cohort
n
pbb
n
control
second
valid
cohort
n
pbb
n
control
interleukin
il
receptor
antagonist
assay
elisa
western
blot
qpcr
togeth
select
pathway
member
neutrophil
relat
molecul
result
children
symptomat
pbb
significantli
higher
level
protein
mrna
also
higher
howev
ratio
lower
pbb
control
level
lower
pbb
treat
resolv
children
recurr
pbb
gene
express
signal
molecul
receptor
associ
kinas
significantli
higher
correl
bal
neutrophilia
durat
sever
cough
symptom
neutrophil
mediat
includ
chemokin
receptor
also
higher
pbb
conclus
pbb
character
increas
pathway
activ
relat
mediat
associ
bal
neutrophil
cough
symptom
diseas
recurr
provid
insight
pbb
pathogenesi
banton
g
bennett
c
hall
g
simpson
telethon
institut
child
health
research
deakin
univers
introduct
recent
improv
neonat
care
result
viabil
infant
lower
gestat
age
increas
number
preterm
survivor
week
gestat
includ
mani
brochopulmonari
dysplasia
bpd
littl
known
whether
gener
preterm
survivor
experi
increas
persist
respiratori
symptom
compar
fullterm
peer
aim
aim
compar
persist
symptom
preterm
fullterm
children
investig
whether
earli
life
factor
predict
children
like
experi
persist
symptom
method
pearson
chi
squar
test
use
compar
persist
symptom
fullterm
children
preterm
children
without
bpd
retrospect
collect
neonat
inform
respiratori
symptom
data
includ
incid
cough
wheez
year
age
collat
previous
collect
research
databas
persist
deem
presenc
symptom
two
time
point
logist
regress
use
investig
earli
life
predictor
persist
cough
wheez
preterm
children
result
preterm
children
like
experi
persist
cough
ci
wheez
ci
compar
fullterm
children
differ
persist
cough
wheez
preterm
children
without
bpd
preterm
children
experienc
higher
incid
upper
lower
respiratori
tract
infect
first
year
life
like
persist
cough
wheez
conclus
preterm
children
like
persist
symptom
compar
fullterm
peer
experi
respiratori
tract
infect
first
year
life
risk
highlight
import
protect
infant
respiratori
infect
may
help
reduc
persist
symptom
later
life
aim
bronchiectasi
major
contributor
chronic
respiratori
morbid
mortal
worldwid
wheez
asthmalik
symptom
airway
hyperrespons
may
occur
peopl
bronchiectasi
physician
often
use
asthma
treatment
patient
bronchiectasi
method
cochran
airway
group
perform
literatur
search
accord
cochran
methodolog
includ
cochran
central
regist
control
trial
clinic
trial
regist
inclus
criterion
random
control
trial
rct
combin
ic
laba
compar
control
placebo
treatment
ic
monotherapi
children
adult
bronchiectasi
relat
cystic
fibrosi
cf
result
abstract
review
includ
one
rct
compar
combin
ic
laba
high
dose
ic
adult
noncf
bronchiectasi
assess
rct
overal
high
risk
bia
data
analys
review
show
receiv
combin
icslaba
stabl
state
significantli
better
transit
dyspnoea
index
mean
differ
md
ci
coughfre
day
md
ci
compar
ic
month
treatment
signific
differ
group
qualiti
life
number
peopl
one
exacerb
lung
function
conclus
insuffici
evid
current
literatur
make
reason
conclus
efficaci
combin
icslaba
adult
children
bronchiectasi
evid
avail
recommend
therapi
individu
base
presenc
absenc
coexist
airway
hyperrespons
consider
advers
event
associ
combin
icslaba
report
young
girl
present
recurr
episod
cough
wheez
dyspnoea
earli
childhood
triall
asthma
medic
continu
suffer
frequent
lower
respiratori
tract
infect
year
age
admit
icu
bilater
patchi
lung
consolid
fever
cough
sever
respiratori
distress
note
melaena
iron
defici
anaemia
need
blood
transfus
salmonellaposit
stool
sampl
detect
next
month
continu
frequent
chest
infect
small
amount
haemoptysi
investig
chest
xray
cxr
acut
episod
show
bilater
diffus
pulmonari
infiltr
bilater
consolid
ground
glass
opac
ct
chest
show
bronchiectat
chang
right
lower
lobe
bronchoalveolar
lavag
fluid
blood
stain
lung
biopsi
confirm
haemosiderinladen
macrophag
exclus
infect
cardiac
immunolog
glomerular
caus
diagnos
idiopath
pulmonari
haemosiderosi
initi
inpati
treatment
iv
methylprednisolon
antibiot
discharg
home
prednisolon
hydroxychloroquin
fail
control
symptom
steroidspar
agent
azathioprin
introduc
need
increas
maximum
toler
dose
mgkgday
gain
effect
control
stop
haemoptysi
requir
sever
cours
highdos
methylprednisolon
intraven
manag
complic
signific
steroid
side
effect
recent
immunoglobulin
therapi
ad
treatment
discuss
approach
toward
diagnosi
challeng
manag
idiopath
pulmonari
haemosiderosi
introduct
exposur
intrauterin
hypoxia
occur
due
varieti
matern
foetal
andor
placent
factor
respiratori
outcom
infant
follow
birth
depend
durat
andor
sever
hypox
insult
aim
determin
effect
matern
chronic
hypoxia
late
gestat
sheep
express
gene
regul
foetal
lung
liquid
reabsorpt
matur
surfact
system
vital
process
aid
success
transit
airbreath
birth
method
chronic
catheter
pregnant
sheep
expos
normoxia
n
hypoxia
n
term
foetus
deliv
measur
tissu
collect
qrtpcr
use
quantifi
lung
mrna
express
gene
regul
sodium
water
reabsorpt
well
surfact
protein
sp
includ
amiloridesensit
epitheli
sodium
channel
enac
subunit
sodium
potassium
activ
transport
pump
atpas
subunit
aquaporin
aqp
spa
b
c
data
analys
use
student
unpair
ttest
p
consid
signific
result
exposur
hypoxia
reduc
matern
vs
mmhg
matern
hypoxia
reduc
foetal
bodi
weight
vs
kg
increas
ratio
bipariet
diamet
hind
limb
lower
length
vs
lung
foetus
hypox
pregnanc
show
increas
mrna
express
enac
spb
c
conclus
matern
chronic
hypoxia
late
gestat
stimul
process
mediat
lung
liquid
reabsorpt
surfact
system
matur
foetu
may
adapt
respons
prepar
possibl
preterm
deliveri
support
british
heart
foundat
nhmrc
australia
jayasuriya
g
robinson
p
king
g
selvadurai
h
children
hospit
westmead
univers
sydney
woolcock
institut
medic
research
background
small
airway
diseas
play
import
role
patholog
pulmonari
complic
occur
post
bmt
howev
convent
pulmonari
function
test
perform
clinic
practic
adequ
assess
function
small
airway
newer
measur
small
airway
function
multipl
breath
washout
mbw
forc
oscil
techniqu
fot
may
facilit
better
understand
pathogenesi
evolut
small
airway
diseas
children
post
bmt
aim
assess
feasibl
measur
small
airway
function
children
post
bmt
use
mbw
fot
method
cross
section
studi
children
three
year
age
larg
bmt
clinic
vari
time
post
bmt
perform
primari
diagnosi
patient
recruit
limit
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
aml
myelodysplasia
share
similar
condit
regimen
pre
bmt
result
date
five
patient
male
age
rang
year
recruit
test
median
age
bmt
year
rang
median
time
post
bmt
year
rang
year
five
patient
allogen
transplant
unrel
donor
fulli
match
sibl
patient
perform
mbw
fot
patient
evid
peripher
airway
abnorm
median
lci
rang
median
sacin
rang
median
scond
rang
hz
median
resist
rang
median
reactanc
rang
conclus
feasibl
children
post
bmt
perform
mbw
fot
test
small
airway
involv
assess
mbw
fot
seen
post
bmt
patient
abil
make
sensit
small
airway
measur
patient
allow
relationship
clinic
paramet
longitudin
chang
examin
subject
vpc
asthma
urgent
gp
visit
asthma
vs
wc
asthma
edhospit
visit
compar
wc
asthma
conclus
mani
cohort
report
wc
asthma
nonus
ic
studi
popul
poor
control
nwc
vpc
guidelin
suggest
group
use
ic
poor
control
associ
greater
use
acut
care
background
asthma
control
patient
despit
use
mediumdos
ic
method
two
ident
phase
iii
random
doubleblind
doubledummi
placebo
pbo
control
parallelgroup
trial
assess
tiotropium
tio
efficacysafeti
patient
symptomat
asthma
prebronchodil
predict
use
mediumdos
ic
budesonid
equival
random
oncedaili
tio
via
soft
inhal
salmeterol
sal
activ
compar
without
inferenti
analysi
pbo
laba
permit
prespecifi
coprimari
end
point
includ
peak
h
trough
respons
wk
result
baselin
characterist
similar
trialstreat
group
random
patient
treat
mean
postbronchodil
predict
tio
dose
show
signific
improv
vs
pbo
mean
chang
baselin
peak
h
wk
ml
tio
ml
tio
greater
pbo
trial
sal
ml
ml
tio
ml
tio
greater
trial
p
sal
ml
trough
respons
wk
ml
tio
ml
tio
greater
trial
sal
ml
ml
tio
ml
tio
greater
trial
p
sal
ml
discontinu
due
advers
event
ae
pbo
tio
tio
sal
fatal
event
ae
balanc
across
treatment
group
conclus
patient
symptomat
asthma
airflow
limit
despit
mediumdos
ic
addit
oncedaili
tiotropium
provid
sustain
bronchodil
efficaci
compar
sal
well
toler
background
despit
current
medic
remain
unmet
need
asthma
control
patient
moder
asthma
receiv
least
ic
analys
acq
data
patient
treat
oncedaili
longact
anticholinerg
bronchodil
tiotropium
symptomat
asthma
despit
treatment
mediumdos
ic
budesonid
equival
method
patient
random
ident
phase
iii
doubleblind
doubledummi
parallelgroup
studi
patient
receiv
tiotropium
placebo
dose
via
soft
inhal
salmeterol
arm
activ
compar
includ
inferenti
analysi
key
inclus
criteria
includ
prebronchodil
predict
acq
score
preplan
pool
analysi
perform
acq
respond
rate
coprimari
end
point
respond
defin
acq
improv
week
result
baselin
characterist
patient
similar
across
trial
treatment
group
mean
baselin
acq
total
score
sd
dose
tiotropium
significantli
improv
acq
respond
rate
week
compar
placebo
respond
tiotropium
p
tiotropium
p
salmeterol
p
conclus
patient
symptomat
asthma
despit
ic
therapi
addit
oncedaili
tiotropium
provid
statist
signific
clinic
relev
improv
asthma
control
similar
acq
respond
rate
observ
tiotropium
activ
compar
salmeterol
halmo
hurdum
zhang
g
khoo
bizzintino
j
frank
k
lindsay
k
keil
cox
goldblatt
j
bochkov
gern
j
suppli
ulrik
c
le
souef
p
la
introduct
human
rhinoviru
hrv
particularli
hrv
speci
c
common
caus
acut
wheez
episod
children
present
hospit
unclear
whether
children
wheez
hrv
suscept
respiratori
virus
aim
determin
whether
children
present
hospit
wheez
exacerb
hrv
hrva
hrvc
increas
rate
recurr
viral
detect
particularli
hrv
whether
famili
respiratori
histori
play
role
method
children
present
hospit
acut
wheez
prospect
recruit
test
respiratori
virus
data
virus
detect
respiratori
sampl
assess
longitudin
may
decemb
obtain
hospit
microbiolog
record
supplement
hrv
test
hospit
respiratori
sampl
retriev
septemb
decemb
parent
respiratori
histori
defin
either
parent
report
asthma
andor
allerg
diseas
result
children
acut
wheez
episod
n
year
hrv
detect
sampl
recruit
hrvc
common
hrv
speci
children
parent
histori
hrvassoci
wheez
exacerb
recruit
increas
incid
rate
ratio
irr
later
hrv
detect
irr
ci
p
compar
hrv
recruit
acut
wheez
hrva
recruit
also
associ
increas
rate
recurr
hrv
detect
irr
ci
p
children
predispos
asthma
allergi
conclus
children
asthmat
atop
predisposit
hrvrelat
wheez
exacerb
warrant
present
hospit
like
subsequ
hrv
detect
hospit
set
thu
may
inher
suscept
hrvrelat
respiratori
ill
introduct
obes
may
risk
factor
exacerb
asthma
mechan
effect
pregnanc
unknown
aim
determin
influenc
matern
bodi
mass
index
bmi
risk
asthma
exacerb
pregnanc
investig
role
respiratori
viral
infect
method
women
asthma
n
particip
prospect
cohort
studi
viral
infect
asthma
exacerb
pregnanc
bmi
record
baselin
week
gestat
categor
healthi
weight
overweight
obes
exacerb
requir
medic
intervent
record
prospect
asthma
control
inhal
corticosteroid
ic
use
exhal
nitric
oxid
feno
lung
function
common
cold
assess
monthli
visit
addit
visit
attend
cold
asthma
exacerb
nasal
throat
swab
collect
suspect
viral
infect
virus
determin
pcr
result
women
overweight
obes
higher
preval
exacerb
pregnanc
healthi
weight
women
p
acq
exacerb
higher
overweightobes
women
median
healthi
weight
women
p
feno
first
exacerb
median
iqr
healthi
weight
group
n
overweight
group
n
obes
group
n
p
overweightobes
women
like
exacerb
associ
pcr
posit
respiratori
viral
infect
healthi
weight
women
p
excess
weight
gain
associ
exacerb
risk
conclus
overweightobes
confer
greater
risk
asthma
exacerb
pregnanc
may
due
increas
suscept
viral
infect
studi
requir
confirm
find
determin
mechan
involv
eckert
b
simpson
j
powel
h
pretto
j
upham
j
gibson
p
princess
alexandra
hospit
hunter
medic
research
institut
univers
newcastl
john
hunter
hospit
introduct
differ
measur
fraction
exhal
nitric
oxid
feno
instrument
well
document
howev
clinic
implic
differ
use
at
feno
interpret
guidelin
describ
aim
document
interinstru
variabl
feno
measur
devic
secondli
investig
implic
variabl
test
result
interpret
adult
clinic
cohort
method
pair
feno
measur
comparison
niox
mino
instrument
ecomed
model
comparison
siever
noa
b
system
perform
at
cutpoint
criteria
ppb
ppb
feno
interpret
appli
test
result
diagnost
perform
mino
correctli
identifi
abnorm
feno
result
calcul
use
ecomed
siever
system
standard
result
express
mean
sd
result
ninetyfour
adult
f
mino
feno
rang
ppb
assess
comparison
averag
differ
small
ppb
mino
interpret
agreement
system
use
cutpoint
comparison
b
compris
adult
f
mino
feno
rang
ppb
mino
tend
lower
feno
valu
differ
ppb
interpret
agreement
comparison
use
cutpoint
comparison
strong
colinear
across
feno
rang
simpl
linear
correct
enabl
precis
correct
interinstru
differ
conclus
feno
measur
handheld
mino
devic
compar
favour
expens
chemiluminesc
analys
interinstru
differ
result
subject
misclassif
rate
clinic
interpret
simpl
correct
reliabl
appli
make
compar
instrument
read
key
word
nitric
oxid
feno
airway
inflamm
asthma
eosinophil
introduct
respiratori
viral
infect
rvi
particularli
human
rhinoviru
hrv
environment
tobacco
smoke
exposur
et
common
caus
asthma
exacerb
essenti
inhal
toxic
substanc
associ
et
detoxifi
minim
potenti
harm
effect
glutathion
defenc
system
crucial
regard
hypothes
variat
glutathion
gene
may
influenc
individu
abil
detoxifi
pollut
lead
suscept
rvi
hrv
subsequ
asthma
exacerb
aim
variant
glutathion
gene
combin
et
exposur
examin
determin
effect
respiratori
viral
infect
method
children
acut
asthma
n
male
age
year
present
emerg
depart
studi
presenceabs
gene
determin
pcr
et
exposur
determin
questionnair
valid
measur
urinari
cotinin
level
subset
children
rvi
common
respiratori
pathogen
determin
hrv
speci
type
use
molecular
method
result
total
n
test
children
rvi
n
expos
smoke
children
infect
hrva
hrvc
respect
children
orand
gene
expos
et
like
infect
hrva
ci
p
ci
p
respect
combin
ci
p
hrvc
pattern
remain
consist
examin
smoke
exposur
mother
father
separ
conclus
presenc
gene
may
lead
increas
suscept
hrva
etsexpos
asthmat
children
elliot
j
mauad
abramson
mckay
k
bai
green
f
jame
sir
charl
gairdner
hospit
univers
medic
school
sao
paulo
monash
univers
children
hospit
westmead
univers
british
columbia
univers
calgari
background
airway
wall
remodel
mechan
airway
narrow
may
differ
differ
inflammatori
phenotyp
asthma
aim
compar
airway
wall
dimens
airway
smooth
muscl
asm
cell
size
number
percent
muscl
shorten
pm
mucu
occupi
ratio
mor
mucu
gland
area
case
asthma
fatal
nonfat
paucigranulocyt
inflamm
pg
n
eosinophil
eo
n
neutrophil
neu
n
mix
eosinophil
neutrophil
mix
n
control
subject
co
n
method
section
airway
h
e
taken
postmortem
lung
airway
wall
dimens
pm
mor
area
densiti
eosinophil
neutrophil
within
inner
airway
wall
estim
cutoff
mean
eosinophil
andor
neutrophil
densiti
moreless
cellsmm
use
categor
case
asthma
contigu
section
stain
haematoxylin
asm
cell
size
number
determin
use
stereolog
techniqu
result
signific
differ
durat
age
onset
asthma
smoke
histori
case
group
howev
pg
less
number
fatal
asthma
case
p
asthma
group
reticular
basement
membran
thick
significantli
increas
eo
neu
mix
group
compar
co
p
thick
asm
layer
significantli
increas
larg
airway
asthma
group
compar
co
p
asm
cell
number
per
mm
airway
increas
eo
mix
compar
co
p
mor
increas
eo
mix
compar
co
pg
case
pg
case
increas
gland
area
compar
co
p
find
similar
fatal
asthma
case
analys
separ
conclus
asm
hyperplasia
increas
lumin
mucu
may
contribut
airway
narrow
asthma
appear
relat
eosinophil
airway
inflamm
background
compar
airway
cut
crosssect
perimet
basement
membran
pbm
use
marker
airway
size
constant
despit
airway
smooth
muscl
shorten
airway
collaps
extent
remodel
basement
membran
perimet
occur
asthma
thought
small
quantifi
aim
compar
pbm
postmortem
lung
asthma
case
n
control
subject
n
anatom
site
within
lung
method
stratifi
techniqu
use
sampl
axial
airway
apic
segment
left
upper
lobe
anterior
basal
segment
left
lower
lobe
nine
equidist
section
gener
airway
taken
lobe
rang
cartilagin
bronchi
termin
bronchiol
pbm
mm
measur
crosssect
airway
stain
haematoxylin
eosin
multipl
linear
regress
analysi
use
pbm
depend
variabl
gender
age
height
lobe
airway
gener
histori
asthma
includ
independ
variabl
subject
enter
random
effect
result
lobe
significantli
relat
pbm
remov
subsequ
analysi
final
model
show
pbm
relat
height
airway
gener
subject
gender
femal
p
age
p
coeffici
asthma
airway
asthma
case
pbm
would
approxim
mm
shorter
similar
airway
control
subject
conclus
asthma
associ
remodel
pbm
could
contribut
overestim
wall
thick
asthma
compar
airway
similar
pbm
control
case
howev
effect
small
would
account
publish
differ
wall
area
observ
case
asthma
simpson
j
gao
p
bain
k
yang
reynold
p
hodg
jame
upham
j
jenkin
c
peter
gibson
p
hunter
medic
research
institut
univers
newcastl
second
affili
hospit
jilin
univers
jilin
china
changchun
central
hospit
jilin
china
univers
queensland
royal
adelaid
hospit
sir
charl
gairdner
hospit
perth
wa
concord
repatri
gener
hospit
nsw
introduct
member
galectin
famili
anim
lectin
function
varieti
biolog
process
includ
inflamm
unclear
antior
proinflammatori
role
asthma
aim
studi
examin
express
bind
protein
bp
adult
difficult
asthma
relat
inflammatori
subtyp
method
particip
n
uncontrol
acq
treat
asthma
underw
clinic
assess
sputum
induct
sputum
dispers
use
dithiotreitol
cytospin
slide
prepar
cell
viabil
differenti
cell
count
record
measur
sputum
supernat
elisa
assess
sputum
cell
use
immunocytochemistri
eosinophil
asthma
defin
sputum
eosinophil
neutrophil
asthma
sputum
neutrophil
paucigranulocyt
asthma
sputum
eosinophil
neutrophil
result
sputum
median
quartil
significantli
reduc
neutrophil
asthma
ngml
compar
eosinophil
ngml
p
paucigranulocyt
asthma
ngml
p
significantli
elev
neutrophil
asthma
ngml
compar
eosinophil
ngml
p
paucigranulocyt
asthma
ngml
p
express
present
airway
macrophag
significantli
associ
airway
neutrophil
macrophag
lymphocyt
proport
r
p
r
p
r
p
respect
conclus
increas
reduc
suggest
activ
may
reduc
neutrophil
asthma
loss
antiinflammatori
function
neutrophil
asthma
may
contribut
inflammatori
imbal
occur
asthma
phenotyp
simpson
j
carrol
gibson
p
yang
reynold
p
hodg
jame
jenkin
c
peter
hunter
medic
research
institut
univers
newcastl
univers
queensland
royal
adelaid
hospit
sir
charl
gairdner
hospit
perth
wa
concord
repatri
gener
hospit
nsw
rational
peopl
asthma
prone
viral
respiratori
infect
link
immun
dysfunct
though
phenotyp
heterogen
increasingli
recogn
asthma
clear
whether
impair
antivir
immun
present
asthmat
subset
studi
examin
hypothesi
immun
dysfunct
asthma
vari
across
differ
inflammatori
phenotyp
method
innat
immun
respons
human
rhinovirus
examin
adult
poorli
control
asthma
mean
age
year
femal
mean
asthma
control
questionnair
acq
score
blood
mononuclear
cell
cultur
two
strain
hrv
cytokin
measur
elisa
inflammatori
phenotyp
character
use
induc
sputum
eosinophil
sputum
eosinophil
neutrophil
sputum
neutrophil
paucigranulocyt
sputum
eosinophil
sputum
neutrophil
mix
granulocyt
sputum
eosinophil
sputum
neutrophil
result
human
rhinoviru
stimul
releas
n
median
pgml
p
valu
h
significantli
lower
neutrophil
asthma
n
pgml
either
eosinophil
n
pgml
p
paucigranulocyt
asthma
n
pgml
p
differ
mix
granulocyt
asthma
n
pgml
p
hrvstimul
synthesi
vari
across
asthma
phenotyp
basal
unstimul
releas
correl
acq
score
across
patient
multivari
analysi
demonstr
hrv
stimul
releas
independ
correl
sputum
neutrophil
proport
inhal
corticosteroid
dose
age
gender
smoke
statu
predict
conclus
asthma
antivir
innat
immun
dysfunct
evid
respons
patient
neutrophil
asthma
abil
inhal
corticosteroid
impair
import
innat
immun
respons
requir
attent
studi
extent
predict
subsequ
risk
infect
asthma
exacerb
remain
determin
alter
composit
extracellular
matrix
ecm
asthmat
airway
may
result
imbal
level
matrikin
endogen
proteas
inhibitor
also
uncontrol
vascular
remodel
increas
number
size
densiti
blood
vessel
within
asthmat
airway
wall
tumstatin
matrikin
deriv
collagen
previous
report
significantli
reduc
asthmat
airway
tissu
tumstatin
possess
antiangiogen
activ
interf
integrin
signal
endotheli
cell
aim
investig
addit
indirect
angioregulatori
role
tumstatin
asthmat
airway
method
primari
human
airway
smooth
muscl
cell
asmc
peopl
without
asthma
stimul
hr
recombin
human
tumstatin
gene
express
assess
use
rtpcr
ecm
array
activ
human
umbil
vascular
endotheli
cell
huvec
seed
asmcderiv
ecm
examin
use
toluidin
blue
stain
quantifi
adhes
transwel
migrat
boyden
chamber
metabol
activ
mtt
result
follow
hr
treatment
tumstatin
asmc
show
increas
matrix
metalloproteinas
n
p
n
p
gene
express
ecm
deposit
tumstatintr
asmc
induc
greater
adhes
huvec
min
n
p
inhibit
huvec
migrat
hr
n
p
effect
metabol
activ
huvec
seed
onto
matrix
hr
n
p
conclus
tumstatin
alter
angiogen
function
pattern
ecm
via
enhanc
proteolyt
activ
asmc
alter
tumstatin
express
activ
airway
may
contribut
chang
composit
arrang
ecm
increas
vasculatur
seen
airway
peopl
asthma
fund
asthma
foundat
nsw
nh
mrc
aim
bronchial
hyperrespons
bhr
obes
asthma
risk
factor
studi
obesitybhr
relationship
produc
conflict
result
hypothes
method
assess
obes
might
influenc
find
use
tasmanian
longitudin
health
studi
tah
data
examin
obes
bhr
middleag
use
three
obes
measur
method
tah
began
n
old
tasmanian
schoolchildren
enrol
stratifi
subsampl
n
resurvey
questionnair
clinic
studi
standard
protocol
methacholin
bronchial
challeng
test
conduct
bhr
defin
mg
methacholin
bmi
waist
circumfer
wc
waisttohip
ratio
whr
assess
obes
logist
regress
comput
odd
ratio
bhr
adjust
sex
smoke
atopi
childhood
bmi
avoid
potenti
confound
asthma
analysi
restrict
asthmafre
particip
n
interact
pvalu
stratumspecif
estim
comput
result
bhr
preval
weight
ci
sex
differ
femal
kgm
increas
bmi
associ
bhr
ci
p
male
p
bmi
kgm
associ
bhr
p
femal
male
p
overweight
bmi
kgm
women
weakli
associ
bhr
p
associ
men
p
greatli
increas
wc
associ
bhr
women
p
men
p
whr
associ
bhr
p
conclus
bmi
wc
associ
bhr
nonasthmat
middleag
women
men
associ
found
whr
bhr
suggest
obes
measur
could
influenc
find
associ
studi
introduct
sever
survey
identifi
patient
selfidentifi
asthma
control
well
control
howev
score
poorli
asthma
control
test
act
aim
character
group
asthma
suffer
dispar
measur
asthma
control
method
onlin
survey
conduct
peopl
age
healthprofession
diagnos
asthma
symptom
asthma
treatment
past
year
sampl
weight
new
zealand
asthma
popul
age
gender
region
use
act
asthma
control
categor
well
control
wc
well
control
poorli
control
correl
particip
selfestim
level
control
result
total
asthma
suffer
particip
survey
respond
selfperceiv
well
complet
control
asthma
well
control
poorli
control
asthma
act
index
group
n
compar
particip
identifi
maori
vs
fewer
postgradu
educ
vs
less
privat
insur
vs
current
smoker
vs
group
report
higher
reliev
use
vs
prevent
use
vs
combin
medic
vs
symptom
control
use
vs
like
discuss
asthma
health
profession
last
month
follow
written
asthma
action
plan
vs
alway
use
spacer
vs
conclus
particip
felt
asthma
well
control
despit
well
control
accord
asthma
control
test
prescrib
medic
manag
plan
may
suggest
health
care
provid
identifi
asthma
group
manag
accord
current
guidelin
introduct
sever
survey
identifi
patient
asthma
selfidentifi
asthma
well
control
howev
score
poorli
asthma
control
test
act
aim
identifi
group
asthma
suffer
dispar
measur
asthma
control
group
perceiv
asthma
well
control
despit
low
act
score
suggest
well
control
asthma
explor
group
investig
marker
qualiti
life
method
onlin
survey
conduct
peopl
age
health
profession
diagnos
asthma
symptom
asthma
treatment
past
year
sampl
weight
new
zealand
asthma
popul
age
gender
region
use
act
asthma
control
categor
wellcontrol
wc
well
control
poorli
control
vpc
particip
self
estim
level
asthma
control
measur
qualiti
life
explor
group
correl
act
measur
result
total
asthma
suffer
particip
survey
respond
selfperceiv
well
complet
control
asthma
well
control
poorli
control
asthma
act
index
group
n
compar
particip
signific
differ
group
rest
particip
term
feel
healthi
calm
enough
energi
want
healthi
thing
best
health
health
consist
life
goal
conclus
survey
open
discuss
determin
well
control
asthmath
patient
health
care
profession
treat
particip
score
well
measur
qualiti
life
creat
ill
appli
act
follow
strict
guidelin
introduct
european
commun
respiratori
health
survey
ecrh
largest
intern
studi
lung
health
young
middl
age
adult
aim
describ
chang
chronic
respiratori
diseas
symptom
preval
adult
age
method
young
adult
particip
ecrh
melbourn
elig
surviv
subject
complet
postal
telephon
screen
questionnair
invit
clinic
test
includ
intervieweradminist
questionnair
main
questionnair
ask
symptom
treatment
health
servic
util
respiratori
diseas
main
questionnair
mq
analys
result
subject
femal
mean
sd
age
year
common
respiratori
symptom
report
short
breath
exert
wheez
nocturn
cough
chest
tight
nocturn
short
breath
daytim
cough
product
cough
short
breath
rest
morn
cough
signific
differ
respiratori
symptom
sex
doctor
diagnos
asthma
report
report
attack
within
last
month
take
medic
asthma
chronic
bronchiti
report
three
report
emphysema
two
copd
short
act
beta
agonist
saba
use
combin
laba
steroid
inhal
conclus
cohort
remain
symptomat
although
diagnos
treat
longitudin
analysi
complet
data
conduct
determin
whether
chang
preval
respiratori
symptom
diseas
year
introduct
fabri
diseas
andersonfabri
diseas
rare
xlink
inherit
lysosom
storag
diseas
result
defici
alpha
galactosidas
result
accumul
globotriaosylceramid
predominantli
result
small
vessel
diseas
within
heart
kidney
nerv
tissu
thought
globotriaosylceramid
accumul
airway
smooth
muscl
result
airflow
obstruct
previou
studi
shown
worsen
obstruct
time
without
treatment
stabil
spirometr
obstruct
enzym
replac
aim
assess
worsen
airflow
obstruct
time
patient
fabri
diseas
assess
reduct
progress
airflow
obstruct
enzym
replac
method
obtain
serial
spirometri
result
patient
regular
review
within
institut
patient
enzym
replac
therapi
chang
spirometri
analys
statist
result
signific
differ
fvc
time
treat
untreat
group
like
account
small
number
patient
within
non
treatment
group
signific
differ
declin
compar
age
age
versu
one
case
improv
sever
airflow
obstruct
back
within
normal
limit
initi
enzym
replac
conclus
within
cohort
appear
worsen
airflow
obstruct
age
appear
reduct
rate
obstruct
progress
enzym
replac
howev
signific
enzym
replac
younger
age
appear
effect
stabil
airflow
obstruct
case
improv
spirometr
valu
axr
observ
studi
data
collect
patient
uncontrol
persist
sever
allerg
asthma
treat
omalizumab
xolair
aim
describ
characterist
sever
refractori
allerg
asthma
sraa
australia
among
axr
particip
method
webbas
post
market
surveil
registri
www
australianxolairregisterorg
establish
character
sraa
use
efficaci
advers
effect
omalizumab
treatment
sraa
result
particip
mean
age
year
male
sraa
clinic
nsw
n
victoria
n
queensland
n
recruit
poor
asthma
control
score
signific
qualiti
life
impair
aqlq
prior
sever
exacerb
rate
year
mainten
oral
corticosteroid
oc
use
addit
mainten
medic
includ
immunosuppress
macrolid
antifung
agent
particip
report
signific
comorbid
particip
rhiniti
better
baselin
lung
function
report
nasal
steroid
use
half
particip
nasal
polyp
use
mainten
oc
oc
use
common
sraa
complic
obes
vs
p
comorbid
cardiovascular
diseas
vs
p
depress
report
associ
wors
asthma
control
baselin
serum
ige
rang
iuml
patient
receiv
pb
approv
xolair
mean
sd
dose
mg
acq
exacerb
reduc
treatment
sever
advers
event
record
patient
one
anaphylaxi
potenti
relat
xolair
conclus
peopl
sraa
report
high
diseas
burden
extens
comorbid
medic
requir
web
base
registri
use
captur
characterist
popul
monitor
treatment
respons
advers
effect
ill
burden
introduct
sarcoidosi
multisystem
granulomat
diseas
unknown
aetiolog
often
term
immun
paradox
peripher
anergi
reduc
delayedtyp
hypersensit
common
antigen
despit
exagger
inflamm
diseas
site
inflamm
site
domin
character
product
tbet
transcript
factor
promot
product
adher
promot
region
gene
increas
transcript
studi
aim
investig
mechan
underpin
immun
paradox
measur
level
tbet
peripher
blood
mononuclear
cell
pbmc
sarcoidosi
patient
mrna
level
poor
proxi
protein
level
therefor
tbet
protein
level
also
measur
pbmc
subject
method
pbmc
isol
patient
sarcoidosi
control
ficol
separ
total
rna
total
protein
extract
pbmc
use
trizol
cell
lysi
buffer
respect
tbet
mrna
measur
use
quantit
realtim
pcr
protein
measur
elisa
tbet
quantit
western
blot
result
see
tabl
parametr
result
present
mean
sd
nonparametr
result
present
median
rang
patient
pvalu
introduct
interleukin
il
pivot
pathogenesi
asthma
eosinophil
oesophag
eoe
administr
recombin
protein
mice
induc
mucu
product
eosinophil
inflamm
airway
hyperrespons
ahr
aim
character
downstream
molecular
signal
pathway
involv
driven
ahr
well
lung
oesophag
inflamm
method
mice
treat
recombin
murin
receiv
midlin
target
sirna
nonsens
control
sirna
ahr
assess
total
lung
resist
dynam
complianc
respons
inhal
methacholin
express
percentag
increas
baselin
pb
molecular
marker
inflamm
assess
qrtpcr
elisa
activ
assess
use
activ
duoset
ic
activ
assay
result
treatment
induc
ahr
upregul
trail
express
increas
treatment
associ
decreas
activ
trail
induct
strongli
attenu
sirna
treatment
restor
activ
attenu
ahr
inflammatori
marker
induc
lung
oesophagu
conclus
signal
newli
discov
axi
induc
ahr
inflamm
restor
activ
target
sirna
protect
driven
pathogenesi
lung
oesophagu
murin
knockdown
cell
control
inject
cell
subcutan
flank
balbc
mice
tumour
dimens
measur
thrice
weekli
anim
sacrif
tumour
reach
mm
knockdown
tumour
growth
significantli
retard
mm
compar
parent
mm
vector
mm
examin
immun
system
involv
regul
mm
tumour
growth
cell
grown
nude
mice
knockdown
tumour
mm
grew
similar
rate
parent
mm
vector
mm
suggest
role
cell
mm
tumour
regul
absenc
explor
cell
deplet
balbc
tumour
bear
mice
use
specif
antibodi
knockdown
tumour
significantli
larger
mice
deplet
cell
isol
mm
mm
combin
mm
compar
nondeplet
control
mm
suggest
cellmedi
respons
orthotop
model
balbc
mice
receiv
singl
intraperiton
inject
knockdown
cell
control
day
anim
sacrif
number
periton
tumour
nodul
enumer
blind
investig
signific
reduct
number
nodul
observ
knockdown
tumour
compar
parent
vector
control
combin
vitro
data
suggest
import
role
pathobiolog
characterist
mm
vivo
repres
novel
therapeut
target
background
hypernatraemia
often
associ
abnorm
fluid
sodium
balanc
associ
advers
outcom
critic
ill
patient
howev
hyperosmolar
secondari
effect
hypernatraemia
lung
protect
cell
cultur
anim
model
induc
hypernatraemia
lead
hyperosmolar
studi
lung
injuri
aim
investig
whether
hyperton
salin
protect
intratrach
lipopolysaccharid
lp
induc
lung
injuri
rat
model
method
immedi
follow
induct
acut
lung
injuri
male
spragu
dawley
rat
receiv
either
hyperton
salin
iv
resuscit
fluid
dosag
design
control
either
sodium
water
load
salin
albumin
albumin
dextros
follow
hour
noninjuri
mechan
ventil
blood
gase
lung
oedema
respiratori
mechan
histolog
lung
injuri
score
assess
result
analys
anova
tukey
posthoc
analysi
result
administr
hyperton
salin
result
hypernatraemia
serum
na
mmoll
mmoll
min
maintain
hour
initi
lung
injuri
administr
hyperton
salin
associ
reduc
lung
injuri
evid
decreas
lung
oedema
p
myeloperoxidas
activ
p
bronchoalveolar
lavag
cell
p
protein
p
p
p
lung
histolog
injuri
score
compar
posit
fluid
control
anim
similarli
lung
physiolog
improv
higher
p
lower
lung
elast
p
associ
preserv
surfact
activ
assess
small
larg
aggreg
ratio
surfact
phospholipid
p
conclus
hypernatraemia
lung
protect
lp
induc
acut
lung
injuri
independ
fluid
sodium
load
introduct
peopl
chronic
obstruct
pulmonari
diseas
copd
impair
antivir
interferon
ifn
respons
influenza
infect
mechan
underli
reduc
induct
copd
howev
unknown
antivir
stress
granul
avsg
enhanceosom
format
import
induct
product
aim
hypothes
format
avsg
enhanceosom
impair
copd
primari
bronchial
epitheli
cell
pbec
influenza
infect
lead
reduc
induct
enhanc
viral
replic
method
pbec
healthi
nonsmok
volunt
subject
copd
infect
human
influenza
moi
avsg
protein
pkr
tiar
detect
immunofluorescenceconfoc
microscopi
western
blot
enhanceosom
protein
also
measur
protein
measur
western
blot
viral
replic
measur
plaqu
assay
pkr
silenc
specif
sirna
infect
coloc
test
perform
use
imagej
accord
instruct
result
influenza
infect
result
reduc
avsg
compon
pkr
tiar
express
decreas
format
avsg
copd
pbec
format
enhanceosom
also
significantli
decreas
copd
pbec
reduc
express
enhanceosom
compon
determin
pkr
import
format
avsg
pkr
inhibit
sirna
led
impair
avsg
format
also
enhanceosom
led
reduc
induct
increas
influenza
viral
replic
copd
pbec
conclus
copd
pbec
impair
format
avsg
enhanceosom
influenza
infect
result
reduc
pkr
protein
express
lead
reduc
protein
product
increas
viral
titr
aim
portabl
oxygen
concentr
poc
lighter
easier
manoeuvr
portabl
oxygen
cylind
howev
abil
meet
oxygen
requir
peopl
interstiti
lung
diseas
ild
exercis
evalu
aim
studi
compar
effect
ambulatori
oxygen
deliv
exercis
use
evergo
poc
ambulatori
oxygen
deliv
portabl
cylind
peopl
ild
method
peopl
ild
desatur
less
walk
test
room
air
recruit
follow
two
practic
test
particip
undertook
use
portabl
oxygen
cylind
use
evergo
poc
random
order
evergo
poc
deliv
puls
flow
maximum
set
whilst
portabl
cylind
set
lminut
continu
flow
particip
pull
oxygen
devic
match
weight
primari
outcom
nadir
result
particip
peopl
ild
ipf
mean
age
sd
year
tlco
mean
durat
onset
symptom
diagnosi
month
anti
gmcsf
antibodi
detect
case
test
complain
exert
dyspnoea
cough
fatigu
weight
loss
chest
tight
present
case
respect
intercurr
infect
seen
patient
singl
whole
lung
lavag
wll
perform
case
one
anaesthetist
perform
major
procedur
patient
triall
gmcsf
rituximab
anoth
gmcsf
trial
conclus
pap
rare
diseas
underlin
import
dedic
team
manag
patient
wll
current
gold
standard
treatment
safe
effect
toxic
particl
inhal
may
frequent
associ
pap
group
aim
skelet
muscl
weak
common
featur
interstiti
lung
diseas
ild
correl
strongli
reduc
exercis
toler
given
potenti
impact
skelet
muscl
function
exercis
toler
skelet
muscl
strength
import
compon
assess
patient
ild
aim
evalu
interrat
intrarat
reliabl
hand
held
dynamomet
measur
muscular
strength
peopl
ild
method
bicep
quadricep
strength
measur
use
jtech
command
powertrack
ii
hand
held
dynamomet
particip
complet
three
consecut
maxim
isometr
contract
muscl
separ
second
rest
within
session
intrarat
reliabl
particip
test
twice
day
two
independ
assessor
random
order
minut
apart
interrat
reliabl
particip
return
week
later
repeat
strength
test
procedur
betweensess
intrarat
reliabl
rel
reliabl
peak
mean
muscl
strength
kg
muscl
estim
use
intraclass
correl
coeffici
icc
result
thirti
particip
ild
vari
aetiolog
ipf
mean
age
sd
year
includ
twenti
particip
complet
interrat
within
session
intrarat
reliabl
protocol
male
femal
fvc
predict
tlco
predict
twenti
one
particip
complet
session
intrarat
reliabl
protocol
male
femal
fvc
aim
investig
role
serum
precipitin
distinguish
hypersensit
pneumon
hp
interstiti
lung
diseas
ild
identifi
optim
threshold
specif
antibodi
level
diagnos
hp
method
consecut
patient
attend
royal
princ
alfr
hospit
ild
clinic
sept
result
serum
precipitin
analys
diagnos
multidisciplinari
review
record
clinic
data
includ
hp
antigen
exposur
serum
precipitin
collect
investig
blind
ild
diagnosi
result
budgerigar
pigeon
jul
farmer
lung
jan
specif
igg
measur
pigeon
budgerigar
poultri
farmer
lung
serum
precipitin
identifi
use
immunoprecipit
sept
analys
result
ild
patient
mean
age
yr
male
serum
precipitin
analysi
diagnos
includ
idiopath
interstiti
pneumonia
n
connect
tissu
diseas
relat
ild
n
hp
n
sarcoidosi
n
ild
n
nonild
n
mean
fvc
dlco
relationship
posit
serum
precipitin
hp
diagnosi
demonstr
ci
p
roc
curv
analysi
reveal
optim
threshold
level
mgl
pigeon
budgerigar
farmer
lung
antigen
respect
sensit
specif
respect
roc
analysi
within
expos
studi
popul
determin
optim
threshold
level
mgl
pigeon
budgerigar
farmer
lung
antigen
respect
improv
sensit
specif
respect
conclus
serum
precipitin
predict
hp
diagnosi
although
limit
poor
sensit
within
unstratifi
ild
patient
diagnost
valu
improv
expos
individu
suspect
ild
shum
b
troy
l
lau
e
webster
taylor
n
cort
p
torzillo
p
cort
royal
princ
alfr
hospit
univers
sydney
introduct
interstiti
lung
diseas
ild
vitamin
vitd
defici
thought
common
associ
connect
tissu
diseas
ctd
poorer
pulmonari
function
clear
whether
vitd
defici
set
impact
bone
densiti
aim
describ
preval
vitd
defici
ild
cohort
relationship
vitd
level
osteopenia
bone
densiti
scan
method
consecut
patient
refer
rpah
ild
clinic
mar
consent
serum
storag
n
male
mean
age
yr
serum
analys
vitd
level
use
liaison
immunoassay
patient
also
concurr
pulmonari
function
bone
densiti
scan
within
month
vitd
insuffici
defin
nmoll
vitd
defici
nmoll
result
ild
diagnos
includ
ctdild
n
granulomat
diseas
n
idiopath
interstiti
pneumonia
iip
n
ild
n
use
vitd
supplement
corticosteroid
bisphosphon
mean
fvc
dlco
vitd
level
nmoll
vitd
insuffici
vitd
defici
vitd
insuffici
associ
underli
ild
diagnosi
vitd
level
higher
take
vit
supplement
weakli
neg
correl
lung
function
tlc
r
p
dlco
r
p
osteopenia
osteoporosi
aim
sever
clinic
case
studi
show
shortterm
treatment
antifung
medic
improv
clinic
statu
diseas
explor
studi
undertaken
treat
patient
follow
till
heal
diseas
method
newli
diagnos
case
sarcoidosi
given
corticosteroid
n
antifung
medic
n
seven
patient
given
drug
view
sever
diseas
patient
follow
xray
determin
degre
granuloma
infiltr
chitotriosidas
cto
angiotensin
convert
enzym
ace
serum
time
till
clinic
heal
diseas
record
well
number
recurr
result
time
till
heal
month
antifung
treatment
month
corticosteroid
ns
regard
xray
score
differ
group
diagnosi
six
month
initi
treatment
heal
granulomat
infiltr
significantli
less
sever
among
antifung
medic
p
respect
number
recurr
also
lower
antifung
group
vs
p
conclus
differ
studi
paramet
compar
treatment
corticosteroid
antifung
medic
presenc
subject
sever
diseas
given
medic
suggest
effici
antifung
treatment
may
limit
less
sever
form
diseas
may
also
reflect
cautionari
attitud
clinician
administ
medic
background
idiopath
pulmonari
fibrosi
ipf
exercis
oxygen
desatur
associ
poorer
outcom
independ
diseas
sever
role
supplement
oxygen
patient
without
rest
hypoxia
clear
studi
effect
supplement
oxygen
compar
air
exercis
endur
distanc
exercis
paramet
ipf
patient
without
rest
hypoxia
six
minut
walk
test
oxygen
desatur
method
ipf
subject
display
oxygen
desatur
without
rest
hypoxia
studi
subject
perform
two
cardiopulmonari
exercis
test
cpet
use
stationari
cycl
ergometri
random
oxygen
medic
air
crossov
doubleblind
fashion
subject
also
complet
two
endur
shuttl
walk
test
eswt
random
lmin
oxygen
medic
air
crossov
doubleblind
fashion
studi
differ
endur
distanc
variabl
oxygen
medic
air
use
student
pair
ttest
result
six
subject
mean
age
yr
five
male
studi
mean
fvc
dlco
rest
nadir
two
subject
pulmonari
hypertens
echocardiographi
cpet
subject
nonsignific
increas
endur
time
supplement
oxygen
compar
air
oxygen
sec
air
sec
p
oxygen
associ
increas
peak
exercis
p
maxim
workload
w
w
p
peak
lmin
lmin
p
oxygen
puls
mlbeat
ml
beat
p
end
tidal
lmin
lmin
p
eswt
oxygen
associ
nonsignific
rise
endur
distanc
compar
air
oxygen
air
p
differ
nadir
peak
hr
borg
dyspnoea
score
whether
subject
receiv
oxygen
air
ipf
patient
exerciseinduc
hypoxia
supplement
oxygen
associ
trend
toward
increas
endur
measur
exercis
perform
compar
medic
air
cpet
eswt
introduct
endotheli
progenitor
cell
epc
rapidli
becom
great
sourc
inform
diseas
process
well
show
potenti
exert
therapeut
effect
cardiac
diseas
model
pulmonari
arteri
hypertens
pah
rare
fatal
diseas
caus
abnorm
cellular
signal
pulmonari
vasculatur
despit
new
era
therapeut
surviv
still
poor
thu
need
understand
pathogenesi
diseas
well
develop
effect
therapi
aim
cultur
epc
whole
blood
taken
pulmonari
arteri
pa
left
ventricl
lv
character
cell
perform
function
analysi
compar
diseas
state
health
control
method
right
heart
catheter
perform
pah
subject
ml
blood
taken
pa
anoth
ml
lv
immedi
follow
mononuclear
cell
isol
wash
seed
gelatin
sigma
coat
well
cell
cultur
endotheli
medium
lonza
week
character
use
flow
cytomteri
result
outgrowth
cell
observ
week
lv
sampl
cultur
week
lv
cell
observ
prolifer
rapidli
week
display
endotheli
like
morpholog
round
cell
cobbleston
appear
flow
cytometr
analysi
character
cell
vonwillibrand
factor
dim
conclus
pilot
studi
identifi
highli
prolif
endotheli
progenitor
cell
popul
display
matur
vascular
endotheli
cellular
marker
may
restrict
downstream
side
pulmonari
vascular
bed
cell
potenti
provid
function
inform
pathogenesi
pah
human
subject
well
potenti
use
surrog
situ
endotheli
cell
evalu
therapeut
gene
deliveri
approach
pah
combin
pulmonari
fibrosi
emphysema
cpfe
rare
clinic
syndrom
condit
occur
simultan
pulmonari
hypertens
known
complic
cpfe
aim
review
approach
manag
individu
cpfe
year
old
exsmok
femal
present
six
month
histori
progress
dyspnoea
sever
hypoxaemia
nyha
class
function
symptom
recurr
hospit
admiss
dyspnoea
attribut
acut
pulmonari
oedema
congest
cardiac
failur
treat
diuret
increas
home
oxygen
transthorac
echocardiogram
echo
one
year
identifi
rapidli
progress
sever
pulmonari
hypertens
rvsp
mmhg
associ
signific
right
ventricular
dilat
reduc
systol
function
sever
tricuspid
regurgit
normal
baselin
pulmonari
function
test
show
preserv
spirometri
lung
volum
progress
declin
ga
transfer
dlcova
l
predict
ct
pulmonari
angiogram
show
upper
lobe
emphysema
lower
lobe
fibrosi
evid
pulmonari
embolu
right
heart
catheter
reveal
least
moder
pulmonari
hypertens
mpap
mmhg
caus
pulmonari
hypertens
exclud
neg
autoimmun
serolog
normal
echo
bubbl
studi
normal
nuclear
medicin
shunt
studi
patient
commenc
oral
sildenafil
mg
thrice
daili
nebul
iloprost
microgram
six
time
daili
warfarin
addit
high
flow
oxygen
increas
diuresi
frusemid
mg
daili
spironolacton
mg
daili
sixminut
walk
distanc
discharg
metr
result
initi
stabil
function
note
symptomat
clinic
improv
three
month
increas
metr
howev
one
year
commenc
treatment
declin
metr
aim
prospect
evalu
impact
specialist
respiratori
physiotherapi
healthrel
qualiti
life
qol
patient
noncf
bronchiectasi
andor
chronic
cough
increas
sputum
product
method
patient
attend
two
outpati
session
min
week
apart
individu
physiotherapi
assess
educ
airway
clearanc
techniqu
act
exercis
use
adjunct
inhal
therapi
senior
cardiorespiratori
physiotherapist
focu
develop
effect
practic
sustain
independ
programm
healthrel
qol
measur
use
leicest
cough
questionnair
lcq
copd
assess
tool
cat
prior
physiotherapi
consult
patient
rate
va
scale
measur
educ
outcom
perceiv
efficaci
session
also
collect
result
patient
femal
mean
age
year
bmi
lmin
predict
ten
patient
establish
home
routin
use
independ
breath
techniqu
use
adjunct
oscil
posit
expiratori
pressur
devic
patient
prescrib
home
exercis
programm
eight
attend
pulmonari
rehabilit
eight
commenc
salin
nebul
adjunct
act
follow
twosess
intervent
signific
improv
coughrel
health
statu
mean
differ
ci
p
lcq
healthrel
domain
physic
psycholog
social
p
total
cat
score
mean
differ
ci
patient
report
increas
understand
bronchiectasi
p
rate
physiotherapi
intervent
help
overal
manag
va
mean
conclus
twosess
physiotherapi
intervent
special
respiratori
physiotherapist
improv
healthrel
qol
patient
primarili
noncf
bronchiectasi
appear
clinic
cost
effect
programm
studi
requir
determin
specialist
outpati
physiotherapi
intervent
may
improv
hospit
cost
util
includ
reduc
hospit
admiss
introduct
pathogenesi
pulmonari
arteri
hypertens
pah
yet
fulli
elucid
modern
theori
implic
aberr
mitochondri
function
downstream
prolifer
apoptosi
resist
pulmonari
arteri
endotheli
smooth
muscl
cell
recent
develop
murin
model
pah
caus
mutat
key
mitochondri
protein
transport
gene
translocas
outer
mitochondri
membran
suggest
mutat
may
also
associ
human
pah
aim
aim
pilot
studi
detect
novel
mutat
known
mutat
occur
alter
frequenc
human
pah
compar
healthi
refer
popul
method
particip
idiopath
pah
ipah
herit
pah
hpah
pah
associ
connect
tissu
disord
elig
inclus
caucasian
popul
sourc
genom
project
act
control
mutat
analysi
perform
direct
sequenc
gene
particip
result
associ
ipah
hpah
minor
allel
singl
nucleotid
polymorph
snp
mutat
previous
associ
human
alzheim
diseas
detect
p
clinic
signific
detect
associ
remain
unclear
snp
may
consid
candid
investig
larger
comprehens
genet
associ
studi
futur
introduct
idiopath
pulmonari
fibrosi
ipf
lethal
respiratori
diseas
effect
treatment
potenti
therapi
diseas
thu
far
fail
translat
success
preclin
murin
model
clinic
set
aim
sought
improv
limit
associ
exist
small
anim
model
fibrosi
use
physiolog
relev
speci
use
lung
segment
model
investig
pulmonari
fibrosi
sheep
method
two
separ
lung
segment
eight
sheep
receiv
two
challeng
two
week
apart
either
u
bleomycin
blm
blm
u
blm
lung
third
segment
receiv
salin
control
lung
function
segment
assess
chang
resist
bal
sampl
lung
tissu
use
assess
inflamm
fibrosi
collagen
content
two
week
final
dose
result
instil
blm
blm
result
promin
fibrosi
patholog
score
blm
blm
vs
salin
p
n
collagen
deposit
isol
lung
segment
sheep
observ
control
compar
blm
dose
blm
dose
segment
reduc
inflammatori
cell
bal
promin
alveolar
epitheli
cell
aec
hyperplasia
observ
lobe
heterogen
pattern
less
signific
loss
alveolar
airspac
volum
fibrosi
observ
blm
segment
blm
vs
blm
p
n
importantli
blm
dose
induc
increas
rest
airway
resist
compar
salin
alon
rseg
increas
baselin
blm
vs
control
vs
p
blm
vs
p
n
result
novel
model
pulmonari
fibrosi
sheep
show
abl
success
induc
fibrot
lesion
featur
reminisc
usual
interstiti
pneumonia
uip
observ
ipf
larg
anim
model
may
potenti
nich
investig
novel
therapi
ipf
diffus
panbronchiol
dpb
distinct
clinicopatholog
syndrom
involv
upper
lower
respiratori
tract
occur
mainli
japanes
rare
report
outsid
far
east
recent
describ
case
seri
melanesian
year
old
aborigin
man
refer
clinic
nodular
lung
diseas
clinic
radiolog
serolog
criteria
dpb
fulfil
case
known
efficaci
low
dose
erythromycin
therapi
demonstr
six
month
treatment
clinic
radiolog
improv
present
first
case
dpb
indigen
australian
man
implic
chronic
respiratori
diseas
includ
bronchiectasi
aborigin
azzopardi
masel
p
laird
p
duncan
thorac
program
princ
charl
hospit
qld
australia
rockhampton
hospit
qld
australia
prior
studi
pap
show
mean
durat
symptom
present
month
rang
month
present
case
male
coal
mine
town
present
region
hospit
acut
sever
hypox
respiratori
failur
extens
bilater
alveolar
opac
mediastin
lymphadenopathi
rash
symptom
includ
week
progress
dyspnoea
product
cough
lethargi
rash
despit
day
oral
corticosteroid
erythromycin
presum
asthma
exacerb
prescrib
gp
background
includ
mild
asthma
pack
year
smoke
routin
blood
test
unremark
inflammatori
marker
rais
treat
unsuccess
broadspectrum
antibiot
hour
bronchoscopi
reveal
milki
secret
transbronchi
biopsi
show
alveolar
fill
eosinophil
pasposit
proteinac
materi
intub
transfer
princ
charl
hospit
receiv
wll
right
lung
litr
day
subcutan
recombin
gmcsf
requir
inotrop
support
postlavag
hour
ga
exchang
improv
discharg
icu
wll
left
lung
perform
day
litr
discharg
home
day
home
oxygen
lminut
antigmcsf
antibodi
titr
bal
fluid
return
posit
skin
biopsi
reveal
spondiosi
nonspecif
inflamm
rash
subsid
treatment
recombin
gmcsf
ceas
week
due
symptomat
ijv
thrombu
wll
lung
requir
within
month
rituximab
commenc
bal
fluid
later
cultur
mycobacterium
intracellular
two
month
follow
rituximab
patient
oxygen
satur
room
air
rest
sputum
product
persist
extens
radiolog
find
conclus
case
illustr
acut
sever
present
autoimmun
pulmonari
alveolar
proteinosi
treat
wll
recombin
gmcsf
rituximab
key
word
pulmonari
alveolar
proteinosi
recombin
gmcsf
whole
lung
lavag
rituximab
introduct
patient
cardiorespiratori
diseas
high
symptom
burden
assess
outpati
set
patient
may
develop
acut
exacerb
may
requir
noninvas
ventil
niv
littl
known
distress
experienc
patient
includ
symptom
burden
delirium
point
preval
date
studi
quantifi
symptom
burden
group
aim
describ
symptom
burden
delirium
point
preval
patient
requir
niv
method
consecut
consent
english
speak
cognit
intact
patient
treat
outsid
icu
niv
hypercapn
respiratori
failur
sydney
teach
hospit
recruit
assess
occur
within
hour
start
niv
symptom
burden
previou
hour
assess
measur
use
condens
memori
symptom
assess
scale
cmsa
scale
assess
peak
bothersom
physic
symptom
rate
frequenc
psycholog
symptom
rate
delirium
point
preval
assess
use
confus
assess
method
icu
camicu
result
fifti
particip
recruit
particip
mean
ph
sd
mean
mmhg
sd
thirtyeight
percent
obstruct
lung
diseas
heart
failur
condit
remaind
caus
respiratori
failur
preval
symptom
breathless
dri
mouth
lack
energi
also
bothersom
symptom
frequent
psycholog
symptom
worri
mean
total
cmsa
sd
mean
physic
symptom
score
sd
mean
psycholog
score
four
screen
posit
delirium
camicu
conclus
breathless
dri
mouth
lack
energi
highli
preval
bothersom
point
preval
delirium
may
underestim
find
highlight
high
symptom
burden
experienc
popul
greater
understand
burden
could
help
address
need
patient
requir
niv
aim
pulmonari
rehabilit
pr
evidencebas
multidisciplinari
intervent
patient
chronic
respiratori
diseas
benefit
includ
decreas
dyspnoea
improv
healthrel
qualiti
life
qol
decreas
healthcar
util
studi
shown
overal
complet
rate
pr
poor
impact
complex
health
issu
aim
studi
review
clinic
data
hospit
rate
patient
complet
gold
coast
hospit
health
servic
gchh
pr
programm
versu
attend
less
session
method
retrospect
review
undertaken
consecut
patient
enrol
gchh
pr
programm
hardcopi
electron
medic
record
review
unpair
ttest
mannwhitney
test
use
compar
complet
fail
complet
pr
pair
ttest
pair
wilcoxon
test
use
compar
baselin
postpr
data
complet
pr
also
attend
less
result
suffici
data
avail
patient
complet
pr
fail
complet
pr
signific
differ
two
group
number
hospit
within
month
follow
pr
signific
improv
st
georg
respiratori
questionnair
sgrq
walk
distanc
baselin
complet
pr
p
signific
improv
sgrq
complet
pr
p
conclus
gchh
pr
programm
outcom
match
publish
data
suggest
qol
function
exercis
capac
significantli
improv
rehabilit
find
reduct
hospit
admiss
post
rehabilit
limit
studi
lack
compar
cohort
commenc
pr
introduct
tsanz
guidelin
state
supplement
therapi
contraind
current
smoker
blood
cohb
elev
smoker
use
screen
patient
smoke
discuss
patient
chronic
haemolyt
anaemia
whose
supplement
prescript
delay
due
persist
elev
cohb
level
smoke
cessat
case
descript
patient
sever
copd
abg
mmhg
mmhg
ph
bicarbon
mmoll
right
heart
failur
stop
smoke
order
qualifi
supplement
therapi
cohb
level
prior
smoke
cessat
post
cessat
n
non
smoker
patient
deni
continu
smoke
measur
elev
cohb
week
period
increas
endogen
cohb
product
due
chronic
haemolyt
anaemia
secondari
pyruv
kinas
defici
consid
like
caus
rais
cohb
patient
prescrib
supplement
cohb
fell
exercis
toler
right
heart
failur
improv
improv
may
result
part
supplement
reduc
capac
endogen
carbon
monoxid
bind
haemoglobin
discuss
cohb
produc
endogen
excess
haemolysi
breakdown
product
red
blood
cell
rais
haemolyt
anaemia
haematoma
breakdown
massiv
transfus
caus
modest
increas
cohb
includ
certain
drug
sever
copd
pregnanc
case
prescript
supplement
delay
due
suspicion
smoke
elev
cohb
recommend
screen
test
measur
cotinin
breakdown
product
nicotin
use
assist
case
cohb
rais
smoke
statu
uncertain
import
elev
cohb
transport
discuss
huang
p
aminazad
parker
k
naughton
charlesworth
young
eastern
health
vic
australia
alfr
vic
australia
introduct
bilevel
noninvas
ventil
niv
standard
care
acut
exacerb
copd
aecopd
acut
respiratori
acidosi
previous
report
icubas
niv
servic
treat
fewer
patient
increas
intub
rate
result
longer
hospit
length
stay
lo
compar
wardbas
servic
anoth
institut
accordingli
implement
wardbas
niv
servic
aim
compar
transit
icu
wardmodel
care
method
prospect
singlecentr
observ
studi
patient
admit
aecopd
acut
respiratori
acidosi
ph
mmhg
treat
niv
first
phase
niv
deliv
exclus
icu
set
subsequ
niv
deliv
wardset
target
milder
group
aecopd
patient
ph
singl
organ
involv
patient
demograph
surviv
intub
rate
lo
physiolog
paramet
record
result
case
treat
icubas
servic
wardbas
servic
signific
differ
patient
demograph
clinic
outcom
mortal
vs
p
intub
vs
p
chang
abg
indic
howev
wardbas
servic
treat
patient
per
month
vs
p
shorter
lo
day
ci
vs
day
ci
p
trend
toward
greater
number
day
receiv
niv
day
ci
vs
day
ci
p
total
hour
niv
receiv
hour
ci
vs
hour
ci
p
conclus
transit
wardbas
niv
servic
enabl
us
treat
patient
result
shorter
lo
whilst
clinic
outcom
noninferior
icubas
deliveri
model
aim
explor
pattern
time
use
peopl
copd
spous
background
distinct
activ
independ
energi
expenditur
influenc
health
differ
way
ie
read
watch
tv
impact
eat
behaviour
cognit
load
differ
use
time
recal
allow
construct
detail
daili
activ
profil
offer
uniqu
insight
time
use
choic
symbiot
relationship
common
coupl
one
member
chronic
diseas
particularli
evid
peopl
copd
avoid
dyspnoea
induc
activ
may
lead
spous
relianc
data
detail
peopl
copd
spous
cohabit
lack
method
peopl
copd
spous
copd
age
yr
spous
age
yr
recal
four
separ
hour
time
use
profil
use
multimedia
activ
recal
children
adult
marca
use
structur
interview
marca
systemat
record
individu
activ
durat
appropri
intens
anchor
point
breakfast
lunch
dinner
discret
activ
embed
adult
marca
contextu
similar
activ
collaps
one
ten
superdomain
sportsexercis
screen
time
transport
quiet
time
selfcar
cultur
work
studi
chore
social
sleep
deviat
predict
superdomain
durat
minday
obtain
averag
four
time
use
profil
particip
regress
superdomain
durat
minday
age
accord
sex
differ
superdomain
durat
spousal
member
assess
use
pair
test
result
peopl
copd
devot
time
superdomain
low
energi
expenditur
activ
preval
screen
time
quiet
time
spous
spous
spent
time
engag
activ
contain
superdomain
chore
social
four
statist
method
use
establish
mid
distanc
one
anchorbas
three
distributionbas
method
result
analysi
use
anchorbas
method
fulfil
requir
correl
coeffici
anchor
health
relat
questionnair
therefor
analysi
termin
analysi
base
cohen
estim
result
mid
metr
chang
prepost
pr
distanc
appli
empir
rule
effect
rang
score
sloan
et
al
gave
mid
metr
lastli
compar
pre
post
pr
chang
score
sgrq
crq
chang
standard
error
mean
sem
sem
defin
baselin
sd
distanc
metr
ci
compar
crq
sgrq
chang
score
establish
crq
sgrq
patient
exceed
mid
compar
propos
averag
threshold
mid
metr
conclus
analys
conduct
respiratori
patient
wide
sever
rang
suggest
mid
chang
metr
previous
suggest
may
higher
requir
evalu
pr
outcom
aim
identifi
particip
environment
factor
may
influenc
outcom
step
test
use
screen
tool
subject
recruit
multicentr
random
crossov
trial
method
patient
stabl
copd
supplement
oxygen
therapi
consid
inclus
multicentr
random
crossov
studi
compar
batteri
power
portabl
oxygen
concentr
portabl
cylind
one
month
step
test
use
screen
tool
ensur
recruit
subject
would
benefit
supplement
oxygen
therapi
administ
either
supplement
oxygen
via
cylind
portabl
concentr
compar
analys
use
investig
particip
environment
factor
includ
gender
age
charleston
comorbid
index
step
height
season
may
influenc
outcom
screen
step
test
recruit
criteria
result
thirtyf
subject
n
screen
qualifi
oxygen
accord
criteria
step
test
particip
pass
femal
mean
age
year
mean
charleston
comorbid
index
age
adjust
index
particip
fail
pass
step
test
femal
mean
age
year
mean
charleston
index
age
adjust
index
subject
pass
step
test
like
test
perform
spring
compar
fail
pass
seventyfour
per
cent
subject
pass
step
test
greater
step
height
cm
compar
subject
fail
pass
lower
step
height
cm
howev
none
factor
produc
statist
signific
differ
group
conclus
none
demograph
environment
factor
produc
statist
signific
effect
step
test
screen
outcom
patient
prescrib
oxygen
supplement
need
regularli
reassess
ensur
still
requir
oxygen
therapi
key
word
oxygen
concentr
cylind
copd
portabl
step
test
qualifi
grant
support
nil
limit
access
pulmonari
rehabilit
pr
australia
result
renew
interest
altern
model
care
copd
stanford
chronic
diseas
selfmanag
cdsm
programm
aim
improv
selfefficaci
may
advantag
given
high
preval
anxieti
depress
copd
effect
anxieti
depress
cdsm
larg
unknown
effect
cdsm
healthcar
util
aim
investig
impact
anxieti
depress
hospit
admiss
particip
undergo
cdsm
method
retrospect
exploratori
analysi
multicentr
random
control
trial
pr
vs
cdsm
prsm
particip
mean
age
year
mean
pred
femal
attend
pr
week
session
n
cdsm
week
session
n
hospit
anxieti
depress
scale
had
score
selfreport
hospit
admiss
record
month
data
analys
via
gener
estim
equat
gee
result
across
group
particip
high
anxieti
score
tendenc
toward
hospit
day
other
p
whilst
anxieti
respond
reduct
point
frequent
hospit
beta
se
p
within
cdsm
group
high
anxieti
associ
hospit
day
beta
se
p
significantli
greater
need
hospit
p
frequent
hospit
p
high
level
depress
affect
outcom
relat
hospit
admiss
effect
cdsm
hospit
differ
anxieti
depress
respond
nonrespond
conclus
effect
stanford
cdsm
programm
hospit
admiss
peopl
copd
appear
influenc
high
level
anxieti
depress
patient
chronic
obstruct
pulmonari
diseas
copd
risk
develop
cognit
impair
due
varieti
reason
report
preval
rate
vari
lack
research
within
australia
preval
impact
cognit
impair
copd
aim
assess
preval
cognit
impair
copd
patient
refer
pulmonari
rehabilit
use
mini
mental
state
examin
mmse
assess
impact
pulmonari
rehabilit
pr
outcom
method
prospect
cross
section
studi
copd
patient
refer
pr
conduct
patient
screen
cognit
impair
use
mmse
six
minut
walk
test
inhal
devic
techniqu
bristol
copd
knowledg
questionnair
selfmanag
scenario
st
georg
respiratori
questionnair
administ
pre
post
pr
result
patient
copd
recruit
mean
sd
age
year
male
mean
sd
baselin
patient
consent
complet
schedul
exercis
session
deem
pr
complet
mean
sd
mmse
score
particip
consid
mild
cognit
impair
mmse
score
particip
normal
rang
differ
proport
complet
pr
accord
cognit
statu
mild
impair
versu
normal
cognit
function
p
conclus
popul
major
patient
refer
pr
normal
cognit
accord
mmse
almost
show
mild
impair
may
reflect
clinician
select
bia
pulmonari
rehabilit
referr
mild
impair
impact
abil
complet
pr
work
requir
assess
effect
sever
cognit
impair
pulmonari
rehabilit
outcom
osadnik
c
mcdonald
c
holland
monash
univers
depart
physiotherapi
vic
la
trobe
univers
school
physiotherapi
vic
institut
breath
sleep
austin
health
vic
austin
health
depart
respiratori
sleep
medicin
vic
alfr
health
depart
physiotherapi
vic
background
sixminut
walk
test
valid
reliabl
wide
use
measur
exercis
toler
copd
repeat
test
recommend
stabl
diseas
howev
necess
acut
exacerb
copd
aecopd
unclear
studi
investig
repeat
aecopd
method
particip
male
mean
age
year
pred
present
hospit
aecopd
sputum
expector
recruit
two
perform
accord
atser
guidelin
hospit
discharg
distanc
walk
compar
via
blandaltman
plot
exploratori
comparison
respond
nonrespond
perform
via
unpair
ttest
result
mean
differ
limit
agreement
wide
compar
nonrespond
respond
n
significantli
lower
smoke
histori
vs
year
p
shorter
length
stay
vs
day
p
trend
toward
rest
vs
p
conclus
mark
variabl
two
day
end
hospit
admiss
copd
exacerb
singl
may
reliabl
measur
function
exercis
toler
immedi
follow
copd
exacerb
aim
examin
relationship
vivo
airway
respons
di
structur
asm
layer
method
subject
control
asthma
copd
due
lung
resect
surgeri
complet
questionnair
respiratori
health
allergi
skin
test
respons
di
assess
bronchodil
inhal
respons
di
determin
ratio
expiratori
flow
measur
maxim
expir
partial
expir
p
submaxim
lung
volum
ie
mp
ratio
postop
tissu
fix
structur
assess
area
asm
numer
densiti
mean
volum
asm
cell
estim
volum
fraction
vv
asm
ecm
within
asm
layer
result
mp
ratio
typic
asthmat
copd
group
indic
bronchoconstrict
follow
di
subject
combin
prebronchodil
mp
ratio
posit
correl
ratio
invers
relat
age
subject
height
weight
prebronchodil
mp
ratio
posit
correl
number
asm
cell
per
volum
favour
reduc
bronchoconstrict
di
mean
asm
cell
volum
vvasm
vvecm
vvother
relationship
postbronchodil
mp
ratio
subject
characterist
lung
function
asm
layer
paramet
conclus
airway
respons
di
relat
volum
densiti
asm
cell
bronchodil
find
suggest
establish
relationship
respons
di
asm
structur
determin
contractil
rather
passiv
properti
asm
aim
littl
evid
guid
whether
repeat
prp
help
ideal
interv
prp
repeat
indic
repeat
subpopul
benefit
prp
repeat
sought
character
patient
popul
repeat
prp
centr
assess
outcom
repetit
prp
method
retrospect
review
year
patient
cld
particip
prp
one
occas
undertaken
assess
outcom
repeat
prp
increas
minut
walk
distanc
data
present
mean
sd
result
patient
complet
prp
septemb
septemb
complet
prp
complet
twice
complet
three
time
complet
four
time
complet
six
time
chang
p
diminish
p
p
l
pre
l
pre
l
pre
conclus
patient
cld
repeat
prp
least
twice
tend
wors
lung
function
time
repeat
still
signific
gain
repeat
prp
although
increas
appear
diminish
repeat
prp
specul
reason
decreas
improv
time
may
relat
worsen
lung
mechan
lander
wiseman
r
gibson
h
walker
j
pitama
beckert
l
new
zealand
institut
commun
health
care
depart
respiratori
medicin
canterburi
district
health
board
nurs
maud
associ
maoriindigen
health
institut
mihi
univers
otago
christchurch
introduct
littl
research
shown
ill
longer
trajectori
chronic
obstruct
pulmonari
diseas
copd
fit
palli
care
servic
develop
cancer
patient
patient
sever
copd
high
often
complic
endoflif
need
current
met
health
servic
transit
time
referr
copd
patient
palli
care
servic
straightforward
prognost
notori
difficult
aim
investig
attitud
opinion
patient
copd
regard
specialist
palli
servic
method
patient
diagnosi
copd
requir
admiss
noninvas
ventil
invit
particip
studi
patient
sever
copd
mani
chronic
respiratori
failur
interview
conduct
focus
understand
health
plan
futur
care
endoflif
issu
induct
analysi
use
draw
three
key
theme
result
patient
sever
copd
perceiv
role
gener
practition
acut
care
psycholog
emot
support
expect
provid
acut
servic
endstag
diseas
connect
secondari
care
mani
want
die
hospit
surround
health
profession
trust
interviewe
see
relev
specialist
palli
care
servic
easytoidentifi
entri
point
servic
need
plan
exit
point
clear
entri
point
secondari
respiratori
servic
identifi
need
plan
exit
point
conclus
specialist
palli
care
servic
charg
extend
servic
chronic
ill
howev
palli
servic
develop
cancer
patient
nt
seem
serv
copd
patient
long
ill
trajectori
demonstr
mismatch
percept
lead
health
system
peopl
live
condit
copd
lee
p
jankelson
banerje
depart
respiratori
sleep
medicin
st
vincent
hospit
darlinghurst
sydney
new
south
wale
australia
academ
depart
sleep
ventil
birmingham
heartland
hospit
heart
england
nh
trust
uk
introduct
arteri
blood
ga
abg
evalu
common
import
aspect
workup
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
defin
respiratori
failur
also
assess
oxygen
requir
accordingli
howev
procedur
risk
particularli
local
injuri
arteri
nerv
haematoma
format
infect
mention
adequ
knowledg
skill
requir
obtain
sampl
aim
studi
aim
assess
whether
venou
blood
ga
vbg
evalu
reliabl
predict
abg
level
patient
admit
aecopd
turn
would
effect
prevent
arteri
punctur
trauma
relat
complic
materi
method
prospect
observ
studi
includ
patient
present
gold
coast
hospit
emerg
depart
admit
respiratori
unit
symptom
aecopd
inform
consent
obtain
patient
underw
abg
vbg
within
hour
admiss
patient
treat
similarli
term
aecopd
result
patient
enrol
studi
compris
male
femal
median
age
rang
year
correl
coeffici
abg
vbg
ph
p
p
p
p
base
excess
p
conclus
studi
demonstr
inde
correl
abg
vbg
paramet
strong
moder
ph
weak
suggest
vbg
may
clinic
util
respiratori
failur
manag
aecopd
patient
limit
studi
small
sampl
size
ongo
studi
allow
us
valid
find
larger
cohort
aim
aim
collect
data
use
gst
compar
heart
rate
recoveri
time
pre
post
pulmonari
rehabilit
pr
group
particip
chronic
obstruct
pulmonari
diseas
copd
copd
progress
natur
symptom
challeng
person
abil
particip
fulli
activ
daili
live
adl
goal
pr
improv
qualiti
life
function
capac
gst
demonstr
respons
chang
person
particip
pr
programm
adl
shower
dri
dress
light
housework
etc
requir
use
unsupport
upper
limb
activ
method
particip
assess
pre
post
pr
intervent
use
gst
standard
manner
data
collect
period
month
particip
exclud
experienc
chest
infect
atrial
fibril
result
intervent
assess
ztest
indic
signific
improv
recoveri
time
averag
reduct
return
baselin
heart
rate
second
confid
interv
maximum
improv
second
reduct
recoveri
time
expect
signific
differ
time
taken
task
howev
worth
note
gener
trend
indic
patient
achiev
task
faster
conclus
groceri
shelv
task
demonstr
true
improv
patient
recoveri
achiev
result
patient
slow
huge
dispar
worldwid
preval
asthma
allergi
still
elucid
hygien
hypothesi
explain
differ
propos
novel
hypothesi
epigenet
dna
methyl
key
compon
may
profound
effect
control
gene
express
therebi
cellular
phenotyp
aim
assess
role
methyl
determin
differ
level
ige
surrog
high
allergi
dispar
observ
genet
similar
karelian
popul
east
west
finnishrussian
border
method
total
serum
ige
level
measur
use
radioallergosorb
test
unicap
methyl
level
cpg
site
promot
gene
determin
finnish
russian
karelian
children
bisulfitetr
dna
sampl
amplifi
subsequ
pyrosequenc
cpg
site
locat
singl
nucleotid
polymorph
snp
site
linkag
function
import
snp
ct
result
methyl
level
site
promot
higher
finnish
karelian
children
respect
compar
russian
children
p
p
respect
methyl
level
promot
site
correl
total
serum
ige
level
russian
children
introduct
intrapulmonari
airway
arteri
import
therapeut
target
mani
lung
diseas
potent
constrictor
smooth
muscl
implic
lung
diseas
asthma
pulmonari
hypertens
lung
slice
techniqu
allow
direct
observ
intrapulmonari
airway
arteri
reactiv
situ
whilst
airway
reactiv
extens
character
assess
vascular
pharmacolog
within
lung
slice
rel
limit
aim
aim
compar
reactiv
intrapulmonari
airway
arteri
rat
intrapulmonari
airway
method
male
spraguedawley
rat
g
use
prepar
lung
slice
briefli
heparin
iu
hbsshepe
inject
right
ventricl
follow
agaros
hbsshepe
trachea
via
cannula
lung
bath
cool
hbsshepe
slice
thick
cut
use
vibratom
overnight
incub
c
chang
airway
arteri
area
within
slice
imag
use
phasecontrast
microscopi
perfus
antagonist
etabbosentan
eta
etb
dilat
agent
result
rat
intrapulmonari
airway
diamet
arteri
contract
similar
level
respons
valu
respect
bosentan
significantli
antagon
contract
airway
arteri
contract
mediat
via
etb
eta
receptor
agonist
salbutamol
relax
intrapulmonari
airway
arteri
novel
dilat
rosiglitazon
abl
elicit
airway
arteri
relax
character
contractil
respons
differenti
respons
dilat
rat
intrapulmonari
airway
arteri
lung
slice
techniqu
appli
diseas
model
explor
mechan
underli
alter
reactiv
assess
novel
therapeut
asthma
pulmonari
hypertens
introduct
achiev
optimum
asthma
control
patient
remain
ongo
challeng
nation
western
health
asthma
exacerb
frequent
patient
high
attend
emerg
depart
ed
low
attend
asthma
clinic
aim
aim
studi
identifi
local
barrier
optimum
asthma
control
commun
method
adult
patient
n
asthma
admit
ed
inpati
ward
outpati
clinic
particip
structur
questionnair
assess
demograph
profil
asthma
sever
medic
exacerb
factor
socioeconom
factor
asthma
educ
wap
usag
physician
n
survey
anonym
onlin
questionnair
regard
usag
barrier
implement
wap
preliminari
analysi
demonstr
mean
sd
age
particip
year
men
non
smoker
tertiari
qualif
psycholog
issu
common
felt
asthma
well
control
asthma
control
questionnair
demonstr
well
control
could
afford
cost
medic
inhal
techniqu
correct
median
rang
present
ed
last
year
asthma
health
literaci
poor
wap
follow
wap
varieti
reason
confid
use
physician
limit
use
wap
includ
lack
time
difficulti
obtain
action
plan
easili
conclus
major
driver
poor
asthma
control
identifi
popul
includ
poor
asthma
educ
coupl
low
uptak
adher
wap
measur
improv
asthma
educ
selfmanag
skill
addit
increas
support
treatment
psycholog
issu
need
explor
introduct
recent
year
incid
asthma
develop
countri
increas
markedli
particular
relev
epidemiolog
studi
show
invers
correl
asthma
incid
chronic
infect
gastric
bacterium
helicobact
pylori
aim
aim
assess
whether
h
pylori
infect
would
attenu
asthmat
phenotyp
mous
model
allerg
airway
diseas
method
infect
adult
femal
mice
n
per
treatment
cfu
proprietari
strain
live
helicobact
pylori
via
gavag
live
h
pylori
use
fulli
activ
capabl
colon
gastric
mucosa
mice
control
mice
gavag
salin
eight
week
infect
mice
subject
standard
system
ovalbumin
sensit
protocol
follow
five
daili
ovalbumin
aerosol
challeng
infect
mice
posit
control
group
neg
control
group
receiv
five
daili
salin
aerosol
twenti
four
hour
last
aerosol
assess
respons
methacholin
mch
via
forc
oscil
techniqu
cellular
inflamm
bronchoalveolar
lavag
result
infect
confirm
via
bacteri
cultur
airway
resist
maximum
dose
mch
significantli
differ
h
pylori
infect
mice
neg
control
mice
group
significantli
lower
airway
resist
maximum
dose
mch
compar
posit
control
posit
control
h
pylori
infect
mice
neg
control
infect
mice
significantli
fewer
eosinophil
significantli
lymphocyt
p
case
lavag
compar
posit
control
conclus
infect
live
h
pylori
significantli
attenu
ovalbumin
induc
allerg
airway
diseas
phenotyp
adult
mice
find
support
notion
exposur
microbi
antigen
live
h
pylori
contribut
normal
immun
system
develop
function
introduct
mous
model
show
prolong
transform
growth
factor
alpha
express
promot
chronic
lung
diseas
particularli
earli
growth
defici
mice
notabl
airway
smooth
muscl
asm
thicken
exagger
increas
lung
resist
follow
bronchoconstrictor
challeng
support
role
airway
diseas
aim
aim
determin
effect
shortterm
express
asm
thicken
develop
airway
hyperrespons
ahr
method
condit
express
airway
epithelium
transgen
mice
clara
cell
secretori
proteinrtta
teto
follow
exposur
doxycyclin
chow
defici
mice
doxycyclin
n
compar
control
group
n
wild
type
receiv
doxycyclin
airway
lung
mechan
assess
forc
oscil
techniqu
lung
fix
subsequ
airway
morphometri
result
asm
thicken
detect
transgen
defici
mice
p
follow
doxycyclin
treatment
ahr
also
demonstr
defin
exagger
increas
newtonian
resist
methacholin
challeng
p
compar
control
comparison
effect
lung
elast
tissu
damp
methacholin
conclus
doxycyclin
express
defici
mice
produc
asm
remodel
ahr
chang
parenchym
mechan
shortterm
express
airway
epitheli
cell
promot
featur
characterist
asthma
grant
support
nhmrc
nih
tran
h
roscioli
e
tan
n
cooksley
c
zalewski
p
wormald
p
vreudg
depart
queen
elizabeth
hospit
depart
medicin
basil
hetzel
institut
translat
health
research
queen
elizabeth
hospit
univers
adelaid
adelaid
south
australia
aim
chronic
rhinosinus
compris
multipl
endotyp
differ
clinic
manifest
respons
therapeut
modal
mechan
differ
poorli
understood
studi
aim
test
hypothesi
inflamm
asthmat
nonasthmat
endotyp
chronic
rhinosinus
nasal
polyp
crswnp
may
mediat
differ
type
inflammasom
method
inflammasomerel
protein
sinu
biopsi
patient
asthmat
n
nonasthmat
crswnp
n
crswnpa
crswnpa
respect
noninflammatori
control
n
studi
mrna
express
whole
tissu
extract
rtpcr
protein
express
local
epithelium
paraffin
section
immunofluoresc
comparison
pcr
express
valu
done
use
compar
delta
ct
method
signific
test
use
student
ttest
result
compar
control
increas
mrna
express
p
detect
fold
fold
fold
crswnpa
crswnpa
respect
protein
level
within
epithelium
chang
express
statist
signific
protein
express
crswnpa
increas
compar
control
crswnpa
p
respect
notabl
nucleartocytoplasm
redistribut
concentr
near
apex
found
specif
epithelium
crswnpa
patient
activ
detect
epitheli
apic
surfac
crswnp
endotyp
control
result
indic
activ
multipl
inflammasom
pathway
crswnp
asthmat
endotyp
crswnp
character
activ
inflammasom
sinunas
epithelium
investig
inflammasom
activ
section
human
airway
asthma
warrant
reddel
h
sawyer
flood
p
peter
australian
school
advanc
medicin
macquari
univers
nsw
royal
children
hospit
univers
melbourn
vic
human
research
ultrafeedback
hawthorn
victoria
woolcock
institut
medic
research
univers
sydney
nsw
introduct
asthma
manag
aim
improv
symptomat
control
reduc
need
urgent
health
care
aim
determin
spectrum
plan
urgent
health
care
profession
hcp
interact
year
australian
current
asthma
method
member
larg
panel
invit
particip
onlin
survey
cohort
select
repres
nation
popul
current
asthma
age
age
gender
state
analysi
reweight
appli
ensur
individu
dataset
repres
within
previou
year
frequenc
plan
urgent
gener
practition
gp
visit
emerg
depart
ed
attend
hospit
visit
discuss
pharmacist
asthma
record
result
respond
everdiagnos
asthma
identifi
stratif
subject
current
asthma
select
complet
survey
cohort
interact
one
hcp
period
rate
attend
weight
popul
period
type
hcp
report
one
two
three
four
six
six
patient
attend
ed
whole
popul
admit
overnight
conclus
urgent
health
care
episod
asthma
remain
common
despit
major
peopl
asthma
report
one
plan
gp
visit
asthma
previou
year
improv
effect
visit
provid
import
opportun
enhanc
asthma
knowledg
refin
asthma
care
improv
asthma
outcom
pharmacist
appear
underutil
clinic
resourc
high
frequenc
sever
childhood
acut
wheez
ill
australia
contribut
larg
proport
hospit
emerg
visit
found
children
present
hospit
acut
wheez
human
rhinoviru
hrv
group
c
children
hrvc
increas
exacerb
sever
number
hospit
admiss
sever
atopi
skin
prick
test
ige
compar
hrvc
unclear
whether
children
acut
wheez
ill
suscept
hrvc
aim
determin
persist
recurr
hrv
speci
children
present
hospit
acut
wheez
control
period
span
winter
method
case
n
recruit
present
hospit
acut
wheez
ill
control
n
commun
flock
nasal
swab
collect
day
everi
two
week
studi
parent
viral
rna
extract
nasal
aspir
revers
transcrib
twostep
pcr
hrv
noncod
region
sequenc
type
statist
analys
complet
use
spss
result
children
mostli
femal
case
control
mean
age
year
case
compar
control
p
follow
mean
day
rang
case
control
differ
persist
mean
vs
respect
p
rate
recurr
median
day
vs
respect
p
differ
persist
hrvc
mean
day
sd
p
compar
hrva
mean
sd
howev
hrvc
hrvb
recur
often
n
fewer
day
median
day
ci
p
other
n
median
conclus
hrvc
recur
faster
hrva
thu
may
either
pathogen
andor
induc
less
host
protect
zoski
g
hart
p
whitehous
kusel
foong
r
chen
l
holt
p
sli
p
hall
g
aim
grow
interest
associ
vitamin
chronic
lung
diseas
includ
asthma
copd
vivo
experiment
data
suggest
earli
life
vitamin
defici
strong
impact
lung
develop
aim
studi
determin
whether
associ
matern
vitamin
statu
postnat
lung
function
children
conduct
subanalysi
data
collect
part
west
australian
pregnanc
rain
cohort
serum
level
oh
measur
time
recruit
week
gestat
measur
immunoassay
lung
function
measur
spirometri
year
age
children
accord
at
guidelin
time
collect
linear
regress
use
assess
associ
matern
serum
oh
lung
function
zscore
gli
refer
equat
logist
regress
use
assess
associ
matern
vitamin
statu
categor
outcom
wheez
asthma
atopi
analys
adjust
relev
confound
eg
matern
asthma
se
foetal
growth
p
male
year
age
conclus
analysi
data
prospect
commun
base
cohort
show
sex
specif
associ
matern
vitamin
statu
lung
outcom
children
data
support
notion
matern
vitamin
import
determin
earli
lung
develop
use
standard
antibiot
sensit
test
assess
individu
isol
cystic
fibrosi
cf
airway
secret
yield
data
question
relev
antibiot
choic
accord
result
improv
clinic
outcom
aim
develop
rapidthroughput
method
assess
proport
antimicrobi
suscept
whole
cf
sputum
identifi
antibiot
combin
like
effect
mix
pseudomon
infect
method
macconkey
broth
contain
singl
combin
antibiot
clinic
eucast
breakpoint
concentr
inocul
homogen
sputum
pseudomonascolon
cf
patient
method
develop
involv
measur
antibiot
suscept
two
method
inhibit
bacteri
growth
optic
densiti
measur
nm
inhibit
bacteri
metabol
activ
use
resazurin
assess
spectrophotometr
perform
plate
format
result
measur
sputum
sampl
highli
reproduc
whether
measur
sampl
overal
icc
p
intrasampl
cov
median
cc
p
intersampl
cov
median
cc
p
duplic
contrast
third
sampl
poorli
reproduc
howev
everi
result
identifi
antibiot
combin
best
choic
tobramycin
meropenem
patient
tobramycinceftazadim
patient
metabol
activ
measur
less
reproduc
overal
icc
p
intersampl
duplic
cov
median
cc
p
good
intrasampl
triplic
cov
median
cc
p
howev
method
also
identifi
best
antibiot
combin
reliabl
although
lower
discriminatori
power
measur
antibiot
high
antimicrobi
efficaci
method
appear
compar
cc
mean
p
conclus
pst
perform
high
throughput
format
feasibl
preliminari
evalu
appear
satisfactori
reproduc
method
even
numer
reproduc
suboptim
sampl
identifi
best
antibiot
combin
impli
util
clinic
tool
conclus
high
flow
oxygen
use
ambul
ed
copd
exacerb
recogn
copd
clinic
signific
hypoxaemia
often
initi
ambul
transfer
continu
ed
larger
studi
would
requir
assess
possibl
harm
approach
educ
involv
emerg
care
may
reduc
risk
complic
hypercapnia
copd
exacerb
perform
pilot
studi
implement
pathway
titrat
inspir
oxygen
target
satur
aim
aim
pathway
time
diagnosi
acut
respiratori
failur
arf
arteri
ph
mmhg
prevent
arf
associ
hyperoxia
minim
arteri
blood
ga
abg
sampl
oxygen
titrat
target
satur
patient
present
emerg
depart
breathless
addit
risk
factor
acut
arf
copd
home
oxygen
posit
airway
pressur
obes
reduc
level
conscious
abg
recommend
oxygen
satur
venou
ph
mmhg
present
result
present
oxygen
satur
target
breath
air
patient
air
oxygen
target
supplement
inspir
adjust
appropri
inappropri
patient
hour
patient
reach
target
oxygen
satur
patient
exceed
target
satur
supplement
oxygen
avf
diagnos
abg
present
patient
avf
diagnos
abg
within
hour
patient
venou
mmhg
present
case
avf
associ
hyperoxia
identifi
abg
indic
pathway
normal
trivial
increas
arteri
associ
venou
mmhg
patient
feedback
user
identifi
handoff
step
caus
delay
failur
achiev
target
aim
exposur
asbesto
lead
develop
lung
cancer
estim
approxim
male
lung
cancer
death
due
asbesto
aim
studi
compar
incid
occup
nonoccup
exposur
asbesto
lung
cancer
control
group
method
structur
telephon
interview
conduct
adult
subject
lung
surgeri
either
lung
cancer
lc
group
clinic
condit
control
group
interview
questionnair
design
survey
lifetim
occup
residenti
asbesto
histori
diy
home
renov
activ
possibl
environment
exposur
result
interview
conduct
particip
lc
control
male
n
signific
differ
incid
occup
nonoccup
exposur
asbesto
group
tabl
aim
home
renov
nonoccup
exposur
asbesto
may
contribut
rise
incid
malign
mesothelioma
australia
aim
studi
compar
frequenc
nonoccup
exposur
asbesto
younger
compar
older
nsw
resid
assess
trend
exposur
method
structur
telephon
interview
conduct
adult
subject
lung
surgeri
variou
clinic
condit
interview
questionnair
design
survey
lifetim
occup
residenti
histori
diy
home
renov
activ
possibl
environment
exposur
subject
year
compar
year
old
result
interview
conduct
particip
subject
year
subject
year
old
male
n
selfreport
diy
exposur
occur
approxim
subject
approxim
subject
report
childhood
exposur
tabl
five
subject
group
subject
group
report
nonoccup
asbesto
exposur
p
aim
proport
patient
mesothelioma
respond
standard
chemotherapi
consist
pemetrex
platinum
tumour
respons
often
becom
blunt
sever
cycl
discov
circumvent
mechan
loss
chemotherapeut
sensit
compar
express
gene
implic
cancer
drug
resist
platinum
platinum
expos
mesothelioma
cell
method
four
mesothelioma
cell
line
expos
stepwis
increment
carboplatin
vitro
toler
carboplatin
establish
control
cell
line
passag
parallel
without
carboplatin
cell
log
phase
growth
cultur
medium
free
platinum
least
two
day
prior
sensit
test
carboplatin
extract
rna
case
report
australian
boatbuild
present
increas
dyspnoea
month
associ
dri
cough
reduc
exercis
toler
least
year
boatbuild
career
heavili
expos
aluminium
dust
ct
chest
show
bilater
patchi
parenchym
infiltr
crazypav
appear
calcifi
mediastin
lymph
node
physic
examin
unremark
spirometri
show
restrict
sixminut
walk
distanc
desatur
four
minut
walk
bronchoalveolar
lavag
return
milkwhit
lipoproteinac
fluid
stain
posit
period
acidschiff
pa
electron
microscopi
show
lamellar
bodi
macrophag
fluid
suggest
alveolar
proteinosi
diagnosi
confirm
gmcsf
antibodi
identifi
lavag
fluid
mediastin
lymph
node
biopsi
reveal
high
level
aluminium
aluminium
oxid
scan
electron
microscopi
energi
dispers
spectroscopi
underw
period
whole
lung
lavag
indic
lung
function
test
symptom
two
year
left
boatbuild
industri
follow
symptom
improv
discuss
alveolar
proteinosi
rare
lung
diseas
character
diffus
accumul
pasposit
lipoproteinac
fluid
alveoli
symptom
nonspecif
restrict
chang
lung
function
typic
autoimmun
nonautoimmun
form
alveolar
proteinosi
describ
latter
encompass
congenit
secondari
caus
silic
inhal
haematolog
malign
commonest
secondari
caus
one
case
link
aluminium
alveolar
proteinosi
far
report
metallurg
analysi
tissu
patient
support
conclus
aluminium
caus
diseas
background
fungi
risk
factor
respiratori
diseas
tradit
exposur
measur
time
consum
take
account
total
fungal
cell
biomass
analysi
enzym
naha
use
measur
total
fungal
biomass
aim
assess
use
naha
techniqu
detect
fungal
damag
perform
measur
home
patient
asthma
sarcoidosi
method
air
sampl
taken
use
filter
cassett
enzym
substrat
ad
fluoresc
read
incub
fluoresc
read
express
naha
unit
um
sampl
taken
build
later
inspect
fungal
damag
n
measur
also
made
bedroom
subject
asthma
n
sarcoidosi
n
result
level
um
build
sensit
specif
presenc
fungi
naha
higher
control
home
person
nocturn
asthma
vs
um
p
among
patient
sarcoidosi
valu
higher
compar
control
vs
um
p
recurr
sarcoidosi
higher
valu
diseas
heal
vs
p
signific
relationship
naha
extent
granulomat
infiltr
amount
bal
result
suggest
measur
airborn
naha
suitabl
detect
presenc
fungi
indoor
particularli
includ
fungal
cell
fragment
level
relat
clinic
express
nocturn
asthma
sarcoidosi
fund
intern
hospit
fund
key
word
sarcoidosi
chitin
introduct
perform
bronchoscopi
commonli
use
investig
patient
possibl
pulmonari
tb
spontan
sputum
smear
neg
current
evid
bal
superior
bw
sputum
smear
neg
pulmonari
tb
gener
consensu
vari
clinician
aim
determin
perform
bal
yield
higher
diagnost
rate
compar
bw
alon
pulmonari
tb
method
prospect
studi
subject
n
possibl
activ
pulmonari
tuberculosi
diagnost
yield
bal
compar
bw
subject
either
produc
sputum
acid
fast
smear
neg
sputum
bal
bw
perform
patient
order
bal
bw
random
primari
outcom
percentag
cultur
posit
result
bw
bal
secondari
outcom
percentag
smear
posit
result
bw
bal
result
interim
analysi
data
n
demonstr
mean
sd
age
year
subject
mainli
vietnam
india
burma
five
subject
cultur
posit
result
bw
bal
one
subject
bw
cultur
neg
mycobacterium
tuberculosi
mtb
bal
cultur
posit
provid
addit
confirmatori
diagnosi
agreement
bw
bal
excel
cohen
kappa
yield
posit
smear
result
low
case
note
bw
bal
conclus
subject
either
expector
sputum
smear
neg
sputum
requir
bronchoscopi
ad
bal
standard
bw
mayb
clinic
indic
given
public
health
issu
import
make
firm
diagnosi
iqr
patient
lunchdot
proport
male
among
clinicdot
homedot
lunchdot
respect
multivari
analysi
homedot
lunchdot
significantli
higher
treatment
success
clinicdot
ci
homedot
lunchdot
compar
clinicdot
conclus
higher
treatment
success
achiev
cdot
especi
lunchdot
tradit
clinicdot
detail
feasibl
costbenefit
analysi
seem
warrant
also
assess
valu
manag
mdrtb
aiyappan
v
nyforthansen
k
mangira
lenghau
morton
flinder
medic
centr
flinder
univers
repatri
gener
hospit
flinder
medic
centr
introduct
antibiot
restrict
polici
place
larg
number
hospit
decreas
emerg
multiresist
organ
prevent
sideeffect
howev
need
effect
restrict
special
unit
assess
previous
aim
compar
antibiot
prescrib
patient
admit
commun
acquir
pneumonia
cap
respiratori
unit
two
teach
campus
within
region
adelaid
flinder
medic
centr
fmc
administr
control
antibiot
prescrib
repatri
gener
hospit
rgh
administr
control
antibiot
prescrib
method
multicentr
retrospect
observ
studi
result
total
patient
admit
diagnosi
cap
fmc
rgh
fmc
femal
rgh
femal
major
patient
rgh
pneumonia
sever
index
psi
score
iv
v
fmc
patient
psi
iii
psi
iv
psi
v
cap
guidelin
follow
patient
fmc
compar
rgh
twotail
fisher
test
p
one
patient
antibiot
associ
advers
event
fmc
compar
none
rgh
one
death
hospit
averag
length
stay
significantli
differ
day
fmc
day
rgh
adher
respiratori
unit
cap
guidelin
studi
high
irrespect
administr
antibiot
restrict
presenc
restrict
increas
adher
guidelin
suggest
well
produc
guidelin
adequ
educ
staff
may
make
prescrib
limit
unnecessari
especi
special
unit
deal
infect
involv
area
expertis
background
aim
aim
experi
assess
level
express
noncyst
fibrosi
bronchiectasi
subject
compar
healthi
control
antiinflammatori
nuclear
receptor
gene
express
wide
lung
low
level
airway
associ
increas
likelihood
p
aeruginosa
posit
cystic
fibrosi
lung
postul
p
aeruginosa
quorum
sens
molecul
lacton
antagon
inhibit
transcript
method
forti
one
noncf
bronchiectasi
subject
healthi
control
underw
fibreopt
bronchoscopi
sampl
collect
lavag
fluid
messeng
rna
extract
sampl
revers
transcrib
total
cdna
use
random
hexam
primer
express
gene
encod
measur
use
real
time
pcr
level
normal
beta
actin
gene
express
result
express
lower
noncf
bronchiectasi
subject
compar
control
p
lower
patient
pcr
posit
p
aeruginosa
p
invers
correl
p
aeruginosa
load
rs
p
seen
either
total
bacteri
load
rs
p
haemophilu
influenza
load
rs
p
express
posit
correl
absolut
macrophag
count
rs
p
consist
invers
correl
p
aeruginosa
total
macrophag
level
rs
p
conclus
express
airway
noncf
bronchiectasi
subject
significantli
reduc
compar
healthi
individu
reduct
correl
lower
level
macrophag
cell
type
gene
highli
express
increas
level
p
aeruginosa
whether
reduct
pure
reflect
low
macrophag
level
due
interact
p
aeruginosa
warrant
studi
introduct
neutrophil
import
control
infect
particular
respiratori
viru
infect
time
increas
neutrophil
number
product
neutrophil
inflamm
associ
sever
asthma
symptom
corticosteroid
insensit
role
viralinduc
asthma
exacerb
neutrophil
directli
respond
respiratori
virus
fulli
understood
aim
investig
neutrophil
activ
viral
surrog
tlr
agonist
differ
infecti
respiratori
virus
identifi
whether
asthmat
nonasthmat
neutrophil
respond
differ
viral
surrog
method
peripher
blood
sampl
collect
mild
asthmat
n
nonasthmat
individu
n
neutrophil
stimul
lp
fmlp
nm
imiquimod
ml
poli
c
rhinoviru
rv
moi
respiratori
syncyti
viru
rsv
moi
influenza
viru
moi
cell
free
supernat
collect
h
measur
neutrophil
elastas
ne
matrix
metalloproteinas
mmp
releas
h
interleukin
il
releas
result
lp
fmlp
imiquimod
stimul
releas
ne
howev
poli
c
induc
releas
differ
asthmat
nonasthmat
neutrophil
respons
except
neutrophil
asthmat
patient
releas
significantli
control
patient
p
rsv
caus
releas
ne
neutrophil
howev
influenza
viru
caus
releas
three
mediat
measur
conclus
neutrophil
detect
respond
viral
surrog
releas
ne
howev
neutrophil
mount
respons
influenza
viru
detect
respond
rsv
respiratori
virus
may
induc
neutrophil
inflamm
directli
form
inflamm
may
result
neutrophil
interact
adjac
infect
cell
background
obes
associ
reduct
frc
may
contribut
increas
airway
closur
tidal
breath
abnorm
ventil
distribut
aim
determin
distribut
airway
closur
measur
nonventil
volum
nvv
obes
bronchoconstrict
method
obes
nonobes
healthi
subject
underw
baselin
postbronchoprovoc
spect
ventil
scan
separ
day
total
lung
volum
nvv
calcul
match
ct
spect
lung
scan
use
previous
describ
algorithm
analysi
lung
divid
upper
middl
lower
third
equal
lung
height
result
baselin
nvv
similar
obes
nonobes
group
nvv
lung
third
proport
total
nvv
nvvprop
less
upper
third
greater
middl
third
obes
compar
nonobes
subject
p
p
respect
similar
lower
third
group
experienc
similar
fall
bronchoprovoc
overal
closur
total
nvv
increas
similarli
group
follow
bronchoprovoc
obes
nvvprop
similar
third
compar
baselin
increas
airway
closur
spread
evenli
across
third
nonobes
group
nvvprop
increas
lower
third
decreas
upper
third
compar
baselin
p
p
respect
therefor
nonobes
group
increas
closur
occur
predomin
lower
third
lung
ventil
increas
upper
third
follow
bronchoconstrict
pattern
airway
closur
differ
obes
compar
nonobes
subject
baselin
bronchoprovoc
differ
pattern
airway
closur
domin
obes
rather
intrins
differ
airway
reactiv
garsk
l
stewart
adam
l
zimmerman
p
princess
alexandra
hospit
institut
health
biomed
innov
qut
griffith
univers
princ
charl
hospit
aim
oxygen
consum
respiratori
muscl
increas
ventil
measur
compar
control
ventil
increas
peripher
muscl
metabol
stay
constant
studi
use
extern
dead
space
ds
reflexli
increas
ventil
rest
subject
sought
valid
novel
measur
use
ds
steadi
state
exercis
compar
repeat
control
condit
rest
exercis
method
singl
blind
random
studi
includ
replic
visit
examin
rest
constant
cycl
exercis
w
condit
control
b
volum
ds
target
ventil
lmin
exercis
c
volum
ds
target
ventil
lmin
exercis
separ
visit
examin
maxim
increment
cycl
exercis
ventil
analys
offlin
correct
flow
alinear
determin
linear
slope
increas
ml
per
increas
ventil
lmin
use
linear
mix
model
limit
agreement
determin
comparison
replic
linear
regress
slope
individu
visit
result
healthi
male
subject
age
se
year
bmi
mllmin
exercis
mll
min
rest
ns
total
match
ventil
increment
exercis
limit
agreement
bia
error
random
error
sd
mllmin
rest
mllmin
exercis
ns
conclus
observ
similar
studi
rest
expect
proport
total
increment
cycl
exercis
abl
validli
measur
ds
steadi
state
exercis
repeat
within
individu
poor
rest
exercis
may
limit
potenti
futur
clinic
use
current
techniqu
introduct
mani
copd
patient
limit
exercis
toler
want
assess
potenti
predictor
symptom
six
minut
walk
distanc
dynam
hyperinfl
dh
shown
limit
exercis
toler
copd
efl
major
determin
copd
measur
noninvas
forc
oscil
techniqu
fot
efl
may
increas
dh
symptom
result
exercis
limit
aim
hypothes
efl
caus
increas
dyspnoea
reduc
method
copd
subject
without
cardiac
failur
orthopaed
comorbid
affect
exercis
capac
recruit
rnsh
pulmonari
rehabilit
depart
spirometri
lung
volum
carbon
monoxid
diffus
capac
dlco
obtain
prior
second
tidal
breath
fot
measur
hz
follow
three
deep
inspir
subject
subsequ
perform
borg
score
dyspnoea
sever
measur
everi
express
slope
borg
vs
distanc
walk
borg
slope
relationship
efl
borg
slope
assess
spearman
correl
result
efl
express
differ
mean
inspiratori
expiratori
reactanc
deltaxr
relat
borg
slope
efl
strongli
relat
dlco
r
great
variabl
borg
slope
rang
borgm
conclus
efl
relat
breathless
howev
may
due
small
number
high
degre
dyspnoea
variabl
selfpac
walk
differ
breathless
requir
studi
loss
airway
tether
lung
elast
recoil
patient
lower
dlco
emphysema
could
explain
correl
efl
dlco
